{"study_id": 76021, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the efficacy of N-Acetylcysteine (NAC) as an adjunctive treatment for clozapine-resistant schizophrenia by conducting a large-scale randomized controlled trial.", "results_summary": "The abstract does not provide specific results but indicates that previous pilot data suggested NAC's efficacy in this population, prompting this larger trial to confirm those findings. The study will measure changes in negative symptoms, quality of life, cognitive functioning, and glutathione concentrations.", "population_specificity": "Patients with clozapine-resistant schizophrenia.", "effective_dosage": "2 g daily of NAC.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:59.690941+00:00"}
{"study_id": 76026, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine in treating cannabis use disorder (CUD).", "results_summary": "The study found that N-Acetylcysteine was effective in treating CUD in adolescents, based on a single trial. No other medications studied for CUD showed efficacy except gabapentin.", "population_specificity": "Adolescents with cannabis use disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:01.187497+00:00"}
{"study_id": 76029, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention N-Acetylcysteine or its effects.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its outcomes.", "population_specificity": "Term and late preterm infants with moderate to severe neonatal encephalopathy.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:02.491980+00:00"}
{"study_id": 76025, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the effect of N-acetyl-L-cysteine (NAC) as a single therapy for sudden deafness compared to a combination of corticosteroids and plasma expander.", "results_summary": "NAC alone (Group A) showed significantly greater mean hearing gain (43 \u00b1 27 dB) and a higher improved rate of hearing (91%) compared to the combination therapy (Group B: 21 \u00b1 28 dB, 57%). The severity of sudden deafness was similar between groups at baseline.", "population_specificity": "70 sudden deafness patients (35 in each group) with no systemic disorders or central signs in electronystagmography.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:02.663890+00:00"}
{"study_id": 76027, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the biotransformation of pyrotinib in humans and identify the major enzymes involved in its metabolism, including N-acetylcysteine conjugation.", "results_summary": "The study identified 24 metabolites of pyrotinib, including 8 phase II metabolites originating from cysteine and N-acetylcysteine conjugation. The principal metabolites were products of O-depicoline and pyrrolidine lactam formation, with fecal clearance as the major excretion route.", "population_specificity": "Humans (specific population not detailed beyond HER2-positive breast cancer context)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "CYP3A4 was identified as the primary enzyme responsible for pyrotinib metabolism, suggesting potential CYP3A-mediated drug-drug interactions.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:03.156676+00:00"}
{"study_id": 76028, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to summarize the literature on preventing contrast-induced acute kidney injury (CI-AKI), focusing on N-acetylcysteine as a potential preventive agent.", "results_summary": "The study found that N-acetylcysteine is one of the most extensively studied agents for CI-AKI prevention, though the abstract does not specify its effectiveness compared to other interventions. It highlights the need for critical clinical appraisal of available data.", "population_specificity": "Patients undergoing coronary angiography, percutaneous coronary intervention, or other diagnostic/interventional procedures involving contrast media.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:03.600715+00:00"}
{"study_id": 76030, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of N-Acetylcysteine (NAC) on alcohol use in adolescents during a marijuana cessation trial and assess whether marijuana reduction influenced alcohol use.", "results_summary": "NAC was associated with reduced alcohol use when marijuana use decreased, but this effect was not observed in the placebo group. The study found no evidence of compensatory alcohol use during marijuana treatment, suggesting NAC may help decrease adolescent alcohol use.", "population_specificity": "Marijuana-dependent adolescents aged 15-21 (N=116).", "effective_dosage": "1200mg twice daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:07.813467+00:00"}
{"study_id": 76032, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to examine current evidence for the use of N-acetylcysteine (NAC) in treating biofilm-related respiratory infections.", "results_summary": "In vitro studies showed NAC effectively inhibits biofilm formation, disrupts preformed biofilms, and reduces bacterial viability. Clinical studies suggest NAC, alone or with antibiotics, may reduce exacerbations in chronic bronchitis, COPD, and rhinosinusitis, but its role in cystic fibrosis and bronchiectasis remains unclear.", "population_specificity": "Patients with biofilm-related respiratory infections (e.g., ventilator-associated pneumonia, cystic fibrosis, bronchiectasis, bronchitis, upper respiratory infections).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:09.383121+00:00"}
{"study_id": 76031, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine whether perioperative administration of N-Acetylcysteine (NAC) could reduce postoperative cognitive dysfunction in elderly noncardiac surgery patients.", "results_summary": "The abstract does not report results, as the study is described as ongoing; it outlines the hypothesis that NAC will reduce cognitive decline post-surgery, measured via neuropsychological tests and biomarker analysis.", "population_specificity": "Elderly noncardiac surgical patients aged 60 years or older.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Perioperative administration (timing not detailed), with follow-up assessments at 7 days, 3 months, and 12 months post-surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:09.452845+00:00"}
{"study_id": 76036, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the effects and mechanisms of action of N-Acetylcysteine and other antioxidants in the treatment of atrial fibrillation.", "results_summary": "The abstract suggests that antioxidants, including N-Acetylcysteine, may reduce lone AF and post-operative AF, potentially decreasing long-term hospitalization time, and are considered a cheap treatment with reduced side effects.", "population_specificity": "Patients with atrial fibrillation (AF), including those with lone AF and post-operative AF.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.087688+00:00"}
{"study_id": 76033, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the efficacy of N-Acetylcysteine (NAC) as an adjunctive treatment for schizophrenia, focusing on its impact on symptom reduction.", "results_summary": "The study found that NAC showed significant reductions in PANSS negative, general, and total scores at 24 weeks in stable chronic schizophrenia patients and at 8 weeks in those experiencing acute exacerbation. However, initial 8-week results in stable patients were less efficacious than placebo.", "population_specificity": "Chronic schizophrenia patients, both stable on antipsychotics and those experiencing acute exacerbation.", "effective_dosage": "Not specified", "study_duration": "8 weeks and 24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.418950+00:00"}
{"study_id": 76034, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine in treating non-acetaminophen-induced acute liver failure, focusing on specific patient populations.", "results_summary": "N-Acetylcysteine improved transplant-free survival in adults with non-acetaminophen-induced acute liver failure, particularly in Coma Grade I-II patients, but did not enhance overall survival. Liver transplantation remained the definitive therapy for advanced cases.", "population_specificity": "Adults with non-acetaminophen-induced acute liver failure, specifically those classified as Coma Grade I or II.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.572366+00:00"}
{"study_id": 76035, "supplement_id": 1364, "safety_score": "30", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to assess the effectiveness and safety of N-Acetylcysteine (NAC) compared to pirfenidone and nintedanib in treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that NAC was not significantly effective in reducing FVC decline or the risk of FVC \u226510% decline over 12 months. Additionally, NAC showed a signal for increased adverse events compared to pirfenidone and nintedanib.", "population_specificity": "3847 IPF patients (2254 treated, 1593 placebo).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.785898+00:00"}
{"study_id": 76037, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare the protective effects of N-acetylcysteine (NAC) plus normal saline (NS) against sodium bicarbonate (NaHCO\u2083) and normal saline alone in preventing contrast-induced nephropathy (CIN) in patients undergoing contrast-enhanced CTPA for suspected pulmonary embolism.", "results_summary": "The study found no statistically significant differences in CIN development rates among the NAC, NaHCO\u2083, and NS groups, with CIN occurring in 23.5%, 21.2%, and 26.4% of patients, respectively. The overall CIN rate was high (23.7%), indicating limited efficacy of the prophylactic treatments.", "population_specificity": "Patients undergoing contrast-enhanced CTPA for suspected pulmonary embolism with at least one risk factor for CIN.", "effective_dosage": "3 mL/kg intravenous NAC+NS (specific NAC dosage not detailed).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:14.954327+00:00"}
{"study_id": 76038, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether combining N-Acetylcysteine (NAC) and sodium bicarbonate (SOB) was more effective than individual use in preventing contrast-induced nephropathy (CIN) after cardiac catheterization and PCI.", "results_summary": "The study found no significant additional benefit in reducing CIN when combining NAC and SOB compared to using either alone, including in subgroups like diabetic patients, those undergoing PCI, or those with baseline renal dysfunction.", "population_specificity": "Patients undergoing cardiac catheterization and percutaneous coronary intervention (PCI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:16.256915+00:00"}
{"study_id": 76040, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine in treating idiopathic pulmonary fibrosis (IPF) among other studied drugs.", "results_summary": "The study found that N-Acetylcysteine, like most other drugs studied, was not able to stop the relentless progression of IPF. Only pirfenidone and nintedanib proved effective in reducing lung function decline and improving patient outcomes.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:16.998246+00:00"}
{"study_id": 76039, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the antidepressant effect of N-Acetylcysteine as an adjunctive treatment for bipolar disorder, particularly in patients with inflammatory comorbidities.", "results_summary": "The study found that N-Acetylcysteine, when used adjunctively with conventional treatments, showed an antidepressant effect in bipolar disorder. However, insufficient evidence exists to support its routine use in BD with inflammatory comorbidities, and further trials are needed.", "population_specificity": "Patients with bipolar disorder, particularly those with inflammatory comorbidities.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:18.356169+00:00"}
{"study_id": 76042, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine the effectiveness of N-acetylcysteine (NAC) as an antioxidant therapy for reducing oxidative stress in patients with obstructive sleep apnea syndrome (OSAS).", "results_summary": "NAC showed promising results in reducing oxidative stress, suggesting it could be a beneficial complementary treatment for OSAS. The study highlighted NAC alongside vitamin C as effective antioxidants in this context.", "population_specificity": "Patients with obstructive sleep apnea syndrome (OSAS).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:18.896534+00:00"}
{"study_id": 76041, "supplement_id": 1364, "safety_score": "30", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to determine whether postoperative N-Acetylcysteine (NAC) infusion could reduce complications, particularly liver failure, in patients undergoing liver resection.", "results_summary": "The study found no significant benefit from NAC in reducing overall complications or liver failure, but noted a significantly higher rate of delirium in the NAC group, leading to early trial termination. Multivariate analysis identified NAC and extensive resections as predictors of postoperative complications.", "population_specificity": "Patients undergoing liver resection.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.438018+00:00"}
{"study_id": 76043, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 60, "study_goal": "The researchers aimed to compare the effectiveness of N-acetylcysteine and intravenous hydration in preventing acute kidney injury caused by contrast dye administration.", "results_summary": "The study found that intravenous hydration was more effective than N-acetylcysteine in reducing the risk of acute kidney injury following contrast dye administration. N-acetylcysteine showed some preventative effect but was less effective compared to hydration.", "population_specificity": "Patients undergoing diagnostic or interventional procedures requiring contrast dye.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.480679+00:00"}
{"study_id": 76044, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to summarize evidence on available therapies, including N-acetylcysteine, for treating severe alcoholic hepatitis.", "results_summary": "The study found that corticosteroids with or without N-acetylcysteine remain the only available therapy for severe alcoholic hepatitis, but specific efficacy data on N-acetylcysteine alone were not detailed.", "population_specificity": "Patients with severe alcoholic hepatitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:20.383709+00:00"}
{"study_id": 76045, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify genetic factors influencing the therapeutic response to N-Acetylcysteine in patients with idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found a variant within TOLLIP associated with differential response to N-Acetylcysteine therapy in IPF patients, suggesting genetic factors may influence efficacy.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF) enrolled in a clinical trial.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:22.261599+00:00"}
{"study_id": 76046, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of N-Acetylcysteine as an adjunctive antioxidant therapy for reducing secondary injury in traumatic brain injury (TBI).", "results_summary": "The study found that N-Acetylcysteine, along with other antioxidants, may be safe and effective in improving clinical outcomes for TBI patients by attenuating oxidative stress-related damage. The overall trend was positive, though limitations were noted.", "population_specificity": "Adult patients with traumatic brain injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:23.873439+00:00"}
{"study_id": 76047, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "To investigate the efficacy and safety of oral N-acetylcysteine (NAC) for preserving residual renal function in patients undergoing hemodialysis.", "results_summary": "NAC improved glomerular filtration rate (GFR) and preserved residual renal function compared to the control group, which showed a decline. The medication was generally well-tolerated.", "population_specificity": "Patients undergoing hemodialysis for at least 3 months with residual urine volume >100 ml/24 h.", "effective_dosage": "Not specified", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:24.720922+00:00"}
{"study_id": 76048, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review neuroimaging literature on pharmacological treatments, including N-Acetylcysteine, to assess their effects on cognitive control in substance use disorders.", "results_summary": "The study found that N-Acetylcysteine, among other medications, improves cognitive control, which is linked to better outcomes in substance use disorders. It highlights the role of enhancing executive control networks and reducing limbic activation as therapeutic targets.", "population_specificity": "Individuals with substance use disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:26.319581+00:00"}
{"study_id": 76049, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to determine whether the toxicity of silver nanoparticles (AgNPs) is caused by silver ions (Ag).", "results_summary": "The abstract does not provide results regarding N-Acetylcysteine's effects.", "population_specificity": "Not specified", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:26.530284+00:00"}
{"study_id": 76050, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 40, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine compared to control for treating idiopathic pulmonary fibrosis through a meta-analysis of clinical trials.", "results_summary": "N-Acetylcysteine showed significant effects only in reducing declines in percentage of predicted vital capacity and 6-minute walking test distance, but no beneficial effects on forced vital capacity, carbon monoxide diffusing capacity, adverse events, or death rates compared to control.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (total of 564 participants across five trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:28.333545+00:00"}
{"study_id": 76052, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether very high-dose NAC (1,800 mg twice daily) would improve respiratory health status in patients with COPD and chronic bronchitis.", "results_summary": "The study found no statistically significant difference in respiratory health status (measured by the St George's Respiratory Questionnaire) or secondary outcomes between NAC and placebo. The trial was terminated early due to potential safety concerns, though no specific adverse events were detailed.", "population_specificity": "Patients with COPD and chronic bronchitis.", "effective_dosage": "1,800 mg twice daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:28.817243+00:00"}
{"study_id": 76051, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and tolerability of oral acetylcysteine combined with pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) and explore its potential efficacy.", "results_summary": "The study found that acetylcysteine did not substantially alter the tolerability profile of pirfenidone but showed no clinical benefit, with possible harmful effects on forced vital capacity (FVC) decline in IPF patients. Adverse events were similar between groups, though photosensitivity was more frequent with acetylcysteine.", "population_specificity": "Patients aged 40-80 with idiopathic pulmonary fibrosis (IPF) already established on pirfenidone therapy.", "effective_dosage": "600 mg, three times daily", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:28.918500+00:00"}
{"study_id": 76053, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential role of N-acetylcysteine (NAC) in determining treatment duration for paracetamol-induced acute liver failure (ALF) and its applicability in non-paracetamol ALF.", "results_summary": "The study found that biomarkers like microRNA-122 and keratin-18 could help predict prognosis in paracetamol-induced ALF, potentially guiding NAC use. However, no firm conclusions were drawn about NAC's efficacy in non-paracetamol ALF.", "population_specificity": "Patients with drug-induced liver injury (DILI), particularly those with paracetamol-induced acute liver failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:31.511840+00:00"}
{"study_id": 76054, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to assess the effectiveness of N-acetylcysteine in improving depressive symptoms in individuals with various psychiatric conditions through a systematic review and meta-analysis.", "results_summary": "N-acetylcysteine significantly improved depressive symptoms and global functionality compared to placebo, with only minor adverse events reported. No changes in quality of life were observed.", "population_specificity": "Subjects with bipolar disorder, major depressive disorder (MDD), trichotillomania, and heavy smoking, all experiencing depressive symptoms.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 to 24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:32.403791+00:00"}
{"study_id": 76055, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effect of N-Acetylcysteine (NAC) on nutritional and antioxidant status in male COPD patients.", "results_summary": "NAC supplementation significantly improved BMI and carbohydrate intake, and increased plasma glutathione levels, indicating enhanced nutritional and antioxidant status. The effects were particularly notable in the NAC group compared to other interventions.", "population_specificity": "Male COPD patients in Kuala Lumpur, Malaysia.", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:32.783949+00:00"}
{"study_id": 76057, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to investigate the efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis (IPF).", "results_summary": "Inhaled N-acetylcysteine attenuated the decline in forced vital capacity (FVC) in IPF patients, particularly in those with greater FVC decline prior to therapy. The mean FVC decline reduced from -170mL to -70mL after 26 weeks of treatment.", "population_specificity": "Patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "352.4mg twice daily.", "study_duration": "26 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:35.302075+00:00"}
{"study_id": 76059, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could modulate liver warm ischemia during hepatic resection and improve postoperative liver function.", "results_summary": "NAC showed a significant favorable recovery in liver function tests compared to placebo when the Pringle maneuver exceeded 70 minutes, with no reported mortality and equal morbidity distribution among groups.", "population_specificity": "48 patients undergoing liver resection with the Pringle maneuver.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:36.824791+00:00"}
{"study_id": 76060, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine could counteract the detrimental effects of ADMA on simvastatin-induced nitric oxide production and angiogenesis.", "results_summary": "N-Acetylcysteine abolished ADMA's negative effects on simvastatin-induced nitric oxide production and angiogenesis by inhibiting NOX-ROS signaling. The study demonstrated that N-Acetylcysteine restored endothelial function impaired by ADMA.", "population_specificity": "Patients with coronary artery disease (clinical cohort) and endothelial cell/in vivo models (experimental studies).", "effective_dosage": "Not specified", "study_duration": "Not specified for N-Acetylcysteine intervention", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:37.969295+00:00"}
{"study_id": 76056, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effect of inhaled N-Acetylcysteine monotherapy on lung function and redox balance in patients with idiopathic pulmonary fibrosis (IPF).", "results_summary": "Inhaled NAC monotherapy improved redox imbalance in early IPF patients, with stable disease patients showing increased reduced-to-oxidized glutathione ratios and decreased oxidized glutathione levels. Baseline GSSG levels \u22651.579\u03bcM were predictive of treatment response.", "population_specificity": "22 untreated early IPF patients (19 men; mean age 71.8\u00b16.3 years).", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:38.945049+00:00"}
{"study_id": 76058, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy, safety, and tolerability of oral N-acetylcysteine (NAC) in improving core social impairment in youth with autism spectrum disorder (ASD).", "results_summary": "NAC was well tolerated and increased glutathione (GSH) levels, but it did not significantly improve social impairment in youth with ASD compared to placebo. No significant differences were found in oxidative stress markers or other secondary outcomes between the NAC and placebo groups.", "population_specificity": "Medically healthy youth aged 4 to 12 years with ASD, weighing \u226515 kg, and judged moderately ill based on the Clinical Global Impressions Severity scale.", "effective_dosage": "Target dose of 60 mg/kg/day in three divided doses (average achieved dose: 56.2 mg/kg/day).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.509669+00:00"}
{"study_id": 76061, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine restores synaptic glutamate uptake and inhibits intrusive thinking in neuropsychiatric disorders.", "results_summary": "The study found that N-Acetylcysteine restores glutamate uptake by astroglial transporters, reducing intrusive thinking, and showed positive effects in clinical trials for addiction, gambling, trichotillomania, and depression.", "population_specificity": "Individuals with neuropsychiatric disorders (e.g., drug addiction, gambling disorder, trichotillomania, depression).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:40.601507+00:00"}
{"study_id": 76063, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate changes in treatment practices, including the use of N-Acetylcysteine, and their impact on survival outcomes in patients with acute liver failure.", "results_summary": "The study found increased use of N-Acetylcysteine over time, particularly in patients with ALF not due to acetaminophen toxicity, correlating with improved 21-day survival rates. The overall and transplant-free survival rates significantly increased during the study period.", "population_specificity": "Adult patients with acute liver failure (ALF) without prior advanced liver disease, enrolled at U.S. tertiary care centers.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:42.334741+00:00"}
{"study_id": 76064, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as a pharmacotherapy adjunct to psychosocial treatment for cannabis use disorder (CUD).", "results_summary": "N-Acetylcysteine was identified as one of the most promising medications for treating CUD, though no pharmacologic treatment has emerged as clearly efficacious. The abstract suggests modest benefits when combined with psychosocial interventions, but abstinence rates remain limited.", "population_specificity": "Individuals with cannabis use disorder (CUD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:43.570621+00:00"}
{"study_id": 76062, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alone or in combination with statins and sodium bicarbonate, reduces the risk of contrast-induced nephropathy (CIN) in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary PCI.", "results_summary": "The study found that the combination of high-dose statin plus NAC (Group III) had the lowest incidence of CIN (14.3%) compared to statin-only groups, with multivariate analysis showing significantly reduced odds of CIN (OR 0.29, p=0.002). NAC's efficacy was highlighted in reducing CIN risk, though its standalone effect was not isolated from statins.", "population_specificity": "STEMI patients undergoing primary PCI (n=334).", "effective_dosage": "NAC 1200mg (frequency not specified).", "study_duration": "Intervention administered within 72 hours post-PCI.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:44.214564+00:00"}
{"study_id": 76067, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-acetylcysteine (NAC) could improve hepatocyte engraftment and prevent early cell loss by inhibiting the instant blood-mediated inflammatory reaction (IBMIR).", "results_summary": "NAC, along with other pharmacological interventions, was shown to successfully inhibit IBMIR in vitro, improving hepatocyte engraftment and function. The study suggests that effective inhibition of IBMIR could enhance transplantation outcomes for liver-based metabolic diseases.", "population_specificity": "In vitro study (not specified for human or animal models).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:47.627531+00:00"}
{"study_id": 76066, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-acetylcysteine is more effective than placebo in reducing compulsive skin-picking behavior in individuals with excoriation disorder.", "results_summary": "N-acetylcysteine treatment led to significant improvements in skin-picking severity compared to placebo, as measured by the NE-YBOCS and Clinical Global Impression-Severity scales. Nearly half of the participants receiving N-acetylcysteine showed much or very much improvement, compared to 19% in the placebo group.", "population_specificity": "66 adults (89% women, mean age 34.8 years) with excoriation (skin-picking) disorder.", "effective_dosage": "1200-3000 mg/day", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:47.860845+00:00"}
{"study_id": 76068, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the antidepressant effect of adjunctive N-Acetylcysteine in the treatment of bipolar depression.", "results_summary": "The study found that N-Acetylcysteine, as part of adjunctive anti-inflammatory therapy, showed a moderate and statistically significant antidepressant effect in bipolar depression. No manic/hypomanic induction or significant treatment-emergent adverse events were reported.", "population_specificity": "Patients with bipolar depression (n = 76 for N-Acetylcysteine).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:48.801922+00:00"}
{"study_id": 76071, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the protective effects of NAC against oxidative stress caused by pesticides in various organs and explore its potential mechanisms of action.", "results_summary": "The study found that NAC exhibits protective effects against pesticide-induced oxidative stress, likely due to its antioxidant properties, including scavenging free radicals and restoring reduced glutathione (GSH) levels. The mechanisms underlying these effects are not fully understood.", "population_specificity": "Not specified (review of existing literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:50.397692+00:00"}
{"study_id": 76069, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of ALF-5755 (a human C-type lectin Reg3\u03b1) in treating non-acetaminophen-induced severe acute hepatitis (SAH), comparing it to placebo.", "results_summary": "ALF-5755 showed no significant benefit in the overall study population but demonstrated a moderate clinical improvement in the HBV/AIH subgroup, including better coagulation protein synthesis and shorter hospitalization.", "population_specificity": "Patients with non-acetaminophen-induced severe acute hepatitis (SAH), including Hepatitis A, HBV, AIH, drug-induced, and other etiologies.", "effective_dosage": "Not specified", "study_duration": "72 hours (primary endpoint measurement)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:50.674981+00:00"}
{"study_id": 76073, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 20, "quality_score": 70, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) supplementation improves \u03b2-cell function and glucose tolerance by reducing oxidative stress in individuals with type 2 diabetes.", "results_summary": "The study found no significant changes in glycemic control, glucose tolerance, insulin release, or oxidative markers with either 600 mg or 1200 mg NAC doses twice daily, suggesting NAC is unlikely to be a valuable therapeutic approach for type 2 diabetes.", "population_specificity": "Middle-aged, obese individuals with relatively well-controlled type 2 diabetes (duration: 0-13 years), treated with diet/exercise alone or metformin.", "effective_dosage": "600 mg and 1200 mg orally twice daily.", "study_duration": "2 weeks for each dosage.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.263140+00:00"}
{"study_id": 76072, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and tolerability of N-Acetylcysteine (NAC) as an augmentative therapy for moderate-to-severe obsessive-compulsive disorder (OCD) when combined with fluvoxamine.", "results_summary": "The study found that NAC significantly improved OCD symptoms, as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), particularly in the obsession subscale, when used alongside fluvoxamine compared to placebo. The results suggest NAC may be effective as an augmentative agent for moderate-to-severe OCD.", "population_specificity": "Patients with moderate-to-severe OCD.", "effective_dosage": "2000 mg daily (NAC) and 200 mg daily (fluvoxamine).", "study_duration": "10 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.793880+00:00"}
{"study_id": 76074, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the angiogenic properties of N-Acetylcysteine and its potential role in modulating therapy outcomes for angiogenesis-related diseases.", "results_summary": "N-Acetylcysteine was found to reduce neovascularization and lower proangiogenic molecule levels, downregulating angiogenesis-related signaling pathways. It demonstrated potential anticancer properties and applicability in angiogenesis-related diseases.", "population_specificity": "Not specified (general discussion of angiogenesis-related diseases)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:56.364297+00:00"}
{"study_id": 76076, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine as an adjunct to tobacco support programs for problem gamblers with comorbid nicotine dependence.", "results_summary": "The study found preliminary evidence supporting the addition of N-Acetylcysteine to tobacco support programs and imaginal desensitisation/motivational interviewing for comorbid nicotine dependence, suggesting potential benefits in this subgroup.", "population_specificity": "Problem gamblers with comorbid nicotine dependence.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:57.128187+00:00"}
{"study_id": 76075, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether pre-operative N-Acetylcysteine (NAC) reduces the incidence of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) and/or percutaneous coronary intervention (PCI).", "results_summary": "The meta-analysis of 43 RCTs found a significant reduction in CIN risk with NAC treatment (OR 0.666; 95% CI, 0.532-0.834). Trial sequential analysis confirmed the robustness of this evidence.", "population_specificity": "Patients undergoing CAG with or without PCI.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:57.473746+00:00"}
{"study_id": 76077, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the role of short-term statin treatment in preventing contrast-induced acute kidney injury (CI-AKI) and clinical adverse events, including the influence of N-Acetylcysteine (NAC) as a co-intervention.", "results_summary": "The study found that short-term statin treatment reduced CI-AKI risk, with benefits observed across subgroups, including those using NAC, but did not specifically isolate NAC's efficacy or safety.", "population_specificity": "Patients at risk of CI-AKI, including statin-na\u00efve patients and East Asians (total n=7746).", "effective_dosage": "Not specified for NAC.", "study_duration": "Short-term (specific duration not detailed).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:00.233704+00:00"}
{"study_id": 76078, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers sought to determine whether shorter courses of intravenous N-Acetylcysteine (NAC) (<21 hours) could be sufficient for treating acute acetaminophen (APAP) overdose without increasing hepatotoxicity risk.", "results_summary": "The study found a low incidence of hepatotoxicity (1.7%) in patients receiving <21 hours of NAC, with no fatalities. Risk-prediction tools (\u03c8 parameter and APAP \u00d7 AT product) suggested low hepatic injury risk when thresholds were met.", "population_specificity": "Patients hospitalized for acute APAP overdose with potentially toxic serum APAP concentrations measured 4-24 hours post-ingestion.", "effective_dosage": "Not specified (intravenous NAC administered for a median of 11.0 hours).", "study_duration": "Median 11.0 hours of NAC treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:01.439093+00:00"}
{"study_id": 76080, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the protective effects of N-Acetylcysteine supplementation on the development and regression of endometriosis.", "results_summary": "The study found that N-Acetylcysteine, along with other nutrients, exerted a protective effect against endometriosis, potentially reducing the risk of disease development and promoting regression.", "population_specificity": "Individuals with or at risk of endometriosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:02.104087+00:00"}
{"study_id": 76082, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to review the therapeutic effects of oxidative stress modulators, including N-Acetylcysteine, for treating cocaine toxicity.", "results_summary": "The study concluded that available oxidative stress modulators, including N-Acetylcysteine, do not appear to have clinical efficacy for treating cocaine toxicity.", "population_specificity": "Preclinical and clinical studies related to cocaine toxicity.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.037972+00:00"}
{"study_id": 76065, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to examine the efficacy of N-Acetylcysteine (NAC) for treating tic severity in pediatric Tourette Syndrome (TS) compared to placebo.", "results_summary": "The study found no significant difference between NAC and placebo in reducing tic severity or improving secondary outcomes like OCD, depression, anxiety, and ADHD. The results contrast with studies showing NAC benefits in adult obsessive-compulsive spectrum disorders but align with a pediatric trichotillomania trial that also found no benefit.", "population_specificity": "Children and adolescents aged 8-17 years with Tourette Syndrome.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.257424+00:00"}
{"study_id": 76081, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 40, "study_goal": "The researchers aimed to evaluate the clinical course and management of warfarin-related nephropathy, including the role of N-Acetylcysteine in stabilizing renal function.", "results_summary": "Temporary interruption of anticoagulation combined with oral N-Acetylcysteine stabilized renal function in a patient with warfarin-related nephropathy. The study suggests N-Acetylcysteine may aid recovery in such cases.", "population_specificity": "A 56-year-old Chinese woman with permanent atrial fibrillation and mechanical valve replacement.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.340685+00:00"}
{"study_id": 76079, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of N-Acetylcysteine and other interventions on mortality and serious adverse events in patients with idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that N-Acetylcysteine was not among the top treatments for reducing mortality in IPF, with nintedanib, pirfenidone, and sildenafil showing higher efficacy. N-Acetylcysteine's ranking for serious adverse events was not specified in the abstract.", "population_specificity": "Adult patients (\u226518 years) with idiopathic pulmonary fibrosis (IPF) as defined by the 2011 criteria.", "effective_dosage": "Not specified", "study_duration": "Average follow-up period of 1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.921741+00:00"}
{"study_id": 76083, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of N-Acetylcysteine, combined with vitamins E, C, and A, on endothelial microparticle profiles and oxidative stress under hypobaric hypoxia conditions.", "results_summary": "The study found no significant difference in oxidative stress markers or endothelial microparticle levels between the treatment group (receiving N-Acetylcysteine and vitamins) and the placebo group, indicating no measurable efficacy of the supplement combination under hypoxic conditions.", "population_specificity": "29 participants during a high-altitude expedition (15 in the final analysis).", "effective_dosage": "Daily dosage (specific amount not provided).", "study_duration": "Duration of the high-altitude expedition (specific length not provided).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:08.399275+00:00"}
{"study_id": 76084, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the efficacy of N-acetylcysteine (NAC) in reducing oxidative stress in chronic hemodialysis patients by measuring total serum anti-oxidant capacity.", "results_summary": "NAC administration significantly increased total anti-oxidant capacity (TAC) compared to placebo (P=0.042), indicating a reduction in oxidative stress. No major side-effects were reported.", "population_specificity": "Chronic hemodialysis patients at Golestan Hospital, Ahvaz, Iran (n=40).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:09.000476+00:00"}
{"study_id": 76086, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety and efficacy of N-acetylcysteine as an adjuvant treatment in patients with acute organophosphorus poisoning.", "results_summary": "N-acetylcysteine reduced atropine requirements and improved oxidative stress markers (decreased malondialdehyde, increased glutathione) but did not significantly affect hospital stay duration. No major adverse effects were reported.", "population_specificity": "30 patients with acute organophosphorus poisoning admitted to a Poison Control Center in Egypt.", "effective_dosage": "600 mg three times daily", "study_duration": "3 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:10.484884+00:00"}
{"study_id": 76089, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 86, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the antioxidant and anti-inflammatory effects of N-Acetylcysteine (NAC) in mitigating markers of inflammation and oxidative stress in liver damage.", "results_summary": "NAC supplementation showed satisfactory results in 85.5% of cases, demonstrating effectiveness in reducing oxidative stress and inflammation markers. However, the abstract calls for more clinical studies to confirm its effectiveness and safety.", "population_specificity": "Animal models and clinical studies (specific population not detailed).", "effective_dosage": "0.204 to 2 g/kg/day (in vivo studies).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:13.826047+00:00"}
{"study_id": 76085, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of high-dose N-Acetylcysteine (NAC) plus hydration, low-dose NAC plus ascorbic acid and hydration, or hydration alone in preventing contrast-induced nephropathy (CIN) in high-risk patients undergoing elective coronary artery intervention.", "results_summary": "High-dose NAC plus hydration (Group A) significantly reduced the incidence of CIN (6.66%) compared to low-dose NAC plus ascorbic acid and hydration (Group B, 16.66%) or hydration alone (Group C, 17.77%). The difference between Group A and the other groups was highly significant, while no significant difference was observed between Groups B and C.", "population_specificity": "High-risk patients undergoing elective cardiac catheterization.", "effective_dosage": "Group A: 1200 mg NAC before angiography and 1200 mg twice daily for three doses; Group B: 600 mg NAC before angiography and 600 mg twice daily for three doses plus ascorbic acid (3000 mg before and 2000 mg after angiography).", "study_duration": "Three doses over a short-term period (exact duration not specified beyond post-angiography follow-up).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.054411+00:00"}
{"study_id": 76087, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to systematically review evidence for the use of N-Acetylcysteine (NAC) as a therapeutic option for non-paracetamol drug-induced liver injury (DILI).", "results_summary": "The study found no significant difference in overall survival between NAC and placebo groups at 3 weeks, but NAC improved transplant-free survival, particularly in non-paracetamol DILI patients. However, the evidence was limited and inconclusive for broader conclusions.", "population_specificity": "Patients with non-paracetamol acute liver failure, including a subgroup with non-paracetamol DILI.", "effective_dosage": "Not specified", "study_duration": "3 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.202350+00:00"}
{"study_id": 76090, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to understand the mechanism of action of N-Acetylcysteine (NAC) in improving survival when used as adjunctive therapy with reduced-intensity hematopoietic cell transplantation (HCT) in childhood cerebral adrenoleukodystrophy (CCALD).", "results_summary": "The study found that NAC therapy increased the expression of antioxidants heme oxygenase-1 (HO-1) (~4-fold) and ferritin (~160-fold) in patient samples compared to baseline. NAC exposure also significantly increased HO-1 expression in normal fibroblasts.", "population_specificity": "School-aged boys with childhood cerebral adrenoleukodystrophy (CCALD).", "effective_dosage": "280 mg/kg/day", "study_duration": "During the course of transplantation (specific duration not detailed in the abstract).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:15.889653+00:00"}
{"study_id": 76088, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers compared the effectiveness of N-Acetylcysteine combined with sodium bicarbonate, isotonic saline, and vitamin C (BS-NAC) against high-volume forced diuresis with matched hydration in preventing contrast-induced acute kidney injury (CIAKI).", "results_summary": "The study found that matched hydration was more effective than BS-NAC in preventing CIAKI, with lower incidence rates (7% vs. 25%) and better long-term outcomes, including reduced major adverse cardiac and cerebrovascular events and hospitalizations.", "population_specificity": "Patients with chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73m\u00b2) undergoing coronary angiography or percutaneous coronary intervention.", "effective_dosage": "Not specified", "study_duration": "Intervention administered for 1 hour before, during, and 4 hours after the procedure.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.686141+00:00"}
{"study_id": 76092, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as a promising agent for improving outcomes in thrombotic thrombocytopenic purpura (TTP).", "results_summary": "The abstract mentions N-Acetylcysteine as a promising agent under evaluation but does not provide specific results regarding its effects in TTP.", "population_specificity": "Patients with thrombotic thrombocytopenic purpura (TTP).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:17.105732+00:00"}
{"study_id": 76091, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to critically analyze NAC's therapeutic potential for wound healing, acute bronchiolitis, and congenital heart defects (CHDs) by reviewing its effects on various disease targets.", "results_summary": "The study concluded that NAC could be used as a therapeutic agent for wound healing, acute bronchiolitis, and CHDs, with future research needed to examine its clinical applications, combination with insulin for CHD prevention, and potential use in PAH treatment.", "population_specificity": "Not specified (review of in vitro and in vivo studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:17.337710+00:00"}
{"study_id": 76093, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to summarize the current treatment options for drug-induced liver injury (DILI), including the role of N-Acetylcysteine (NAC) in treating both acetaminophen poisoning and non-acetaminophen DILI.", "results_summary": "The study found that NAC is the only specific antidote for acetaminophen-induced DILI and may also be beneficial in some cases of non-acetaminophen DILI in adults. However, its efficacy outside acetaminophen poisoning remains less established compared to other treatments like corticosteroids for autoimmune-related DILI.", "population_specificity": "Adults with drug-induced liver injury (both acetaminophen and non-acetaminophen cases).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:20.522362+00:00"}
{"study_id": 76094, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers compared the antioxidant-like effects of timolol with other antioxidants, including N-Acetylcysteine, in diabetic cardiomyopathy.", "results_summary": "The study suggested that N-Acetylcysteine, like timolol, may protect the diabetic heart by scavenging oxidative agents and preventing RyR2 hyperphosphorylation, thereby reducing Ca(2+) leakage from the sarcoplasmic reticulum.", "population_specificity": "Streptozotocin-diabetic rats", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:22.948955+00:00"}
{"study_id": 76095, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could reduce inflammatory biomarkers in pediatric patients with acute pyelonephritis.", "results_summary": "The study found no significant differences between NAC and placebo groups in reducing inflammatory biomarkers (procalcitonin, CRP, leukocyte count) or resolving clinical symptoms (pyuria, bacteriuria). CRP decreased in both groups, but NAC did not outperform placebo.", "population_specificity": "Children under 15 years old diagnosed with acute pyelonephritis.", "effective_dosage": "Daily dose based on weight (exact amount not specified), administered as effervescent tablets for 5 days.", "study_duration": "5 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:23.235532+00:00"}
{"study_id": 76097, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate common weaknesses in preclinical study design and reporting for AKI research, focusing on N-acetylcysteine's potential to prevent contrast-induced AKI.", "results_summary": "The study identified flaws in preclinical AKI research design that hinder translation to clinical practice, but did not provide conclusive evidence on N-acetylcysteine's efficacy for preventing contrast-induced AKI.", "population_specificity": "Preclinical AKI research models (not specified if human or animal).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:23.981979+00:00"}
{"study_id": 76096, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the clinical safety and neuroprotective effects of antenatal and postnatal N-acetylcysteine (NAC) in newborns exposed to maternal chorioamnionitis.", "results_summary": "NAC preserved cerebrovascular regulation and increased anti-inflammatory interleukin-1 receptor antagonist while reducing proinflammatory vascular endothelial growth factor, with no adverse events reported.", "population_specificity": "Mothers >24 weeks gestation with clinical chorioamnionitis and their infants (24 total).", "effective_dosage": "Antenatal: 100 mg/kg/dose every 6 hours; Postnatal: 12.5-25 mg/kg/dose every 12 hours for 5 doses.", "study_duration": "Antenatal until delivery; postnatal for 5 doses (approximately 60 hours).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.150289+00:00"}
{"study_id": 76098, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to review the clinical findings of liver complications in adult dengue patients, including the use of N-Acetylcysteine as an intervention for acute liver failure.", "results_summary": "The abstract mentions N-Acetylcysteine as part of current interventions for treating acute liver failure in adult dengue patients, but specific efficacy results are not detailed. High-level ALT during the febrile stage was associated with shock, suggesting liver complications may predict severe outcomes.", "population_specificity": "Adult patients with dengue infection experiencing liver complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:25.198983+00:00"}
{"study_id": 76100, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of combining pirfenidone with high-dose N-acetylcysteine (NAC) on forced vital capacity, walking distance, and progression-free survival in Chinese IPF patients.", "results_summary": "NAC combined with pirfenidone showed significant improvements in FVC and \u0394SPO2 at 24 weeks, but these effects did not persist to 48 weeks. However, pirfenidone with NAC prolonged progression-free survival compared to placebo with NAC.", "population_specificity": "Chinese IPF patients with mild to moderate pulmonary function impairment.", "effective_dosage": "1800 mg per day of NAC.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:26.041431+00:00"}
{"study_id": 76099, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether preoperative N-acetylcysteine administration could reduce systemic inflammation and oxidative damage in patients undergoing lung resection.", "results_summary": "N-acetylcysteine increased postoperative plasma thiol concentration but showed no significant difference in biomarkers of inflammation, oxidative damage, or clinical outcomes compared to placebo. The study concluded that N-acetylcysteine did not attenuate postoperative inflammation or oxidative damage.", "population_specificity": "Adults undergoing lung resection (a model of acute lung injury).", "effective_dosage": "240 mg/kg over 12 hours.", "study_duration": "Preoperative infusion (12 hours).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:26.465463+00:00"}
{"study_id": 76101, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine could strengthen frontostriatal connectivity, reduce nicotine withdrawal, and help smokers maintain abstinence.", "results_summary": "N-Acetylcysteine was associated with stronger frontostriatal connectivity, reduced craving, higher positive affect, and better abstinence maintenance compared to placebo.", "population_specificity": "Healthy adult, non-treatment seeking smokers (N=16).", "effective_dosage": "2400mg daily (1200mg twice a day).", "study_duration": "3.5 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:28.671141+00:00"}
{"study_id": 76104, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the antidepressant efficacy of N-Acetylcysteine compared to placebo or other treatments in adults with unipolar major depressive disorder.", "results_summary": "The abstract does not provide specific results for N-Acetylcysteine, only noting it was included in one study among several glutamate receptor modulators. No significant results were reported for N-Acetylcysteine.", "population_specificity": "Adults with unipolar major depressive disorder (specific severity not detailed for N-Acetylcysteine subgroup).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:32.461002+00:00"}
{"study_id": 76103, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) reduced liver injury during laparoscopic sleeve gastrectomy (LSG) in patients with fatty livers.", "results_summary": "NAC did not significantly reduce liver enzyme levels, liver injury scores, or secondary inflammatory markers compared to the control group. The study found no significant differences in complications, length of stay, or post-operative inflammatory response between the NAC and control groups.", "population_specificity": "Patients undergoing laparoscopic sleeve gastrectomy (14 females, mean age 44.5 years, mean BMI 60.8 kg/m\u00b2).", "effective_dosage": "Not specified", "study_duration": "Intraoperative infusion (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:32.802856+00:00"}
{"study_id": 76102, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the long-term effects of N-Acetylcysteine (NAC) on plasma homocysteine (tHcy) levels, blood pressure, and thiol redox state in middle-aged men, controlling for factors like hyperlipidemia and smoking.", "results_summary": "NAC significantly reduced postabsorptive plasma tHcy by 11.7% and increased cysteine levels by 28.1%, while also lowering systolic and diastolic blood pressure, particularly in hyperlipidemic men. The effects were consistent regardless of lipid or smoking status.", "population_specificity": "Unmedicated middle-aged men, stratified into hyperlipidemic (n=40) and normolipidemic (n=42) groups, further divided by smoking status.", "effective_dosage": "1.8 g/day (oral)", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.126842+00:00"}
{"study_id": 76105, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) supplementation could compensate for age-related declines in glutathione synthesis and improve health outcomes in the elderly.", "results_summary": "NAC supplementation was found to restore youthful glutathione levels, leading to favorable effects on vascular health, muscle strength, bone density, immunity, inflammation, cognitive function, neurodegeneration, and influenza outcomes in aging humans and rodents. The study suggests that increased cysteine availability from NAC may explain the benefits of higher protein intake in the elderly.", "population_specificity": "Aging humans and rodents (particularly those over 65 years old).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.199147+00:00"}
{"study_id": 76108, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to summarize the potential role of N-Acetylcysteine as an immunomodulatory nutrient in the primary prevention of necrotizing enterocolitis (NEC) in preterm very low birth weight infants.", "results_summary": "The abstract indicates that N-Acetylcysteine is among the nutrients considered for NEC prevention, but current evidence is insufficient, requiring further investigation in animal studies and clinical randomized controlled trials.", "population_specificity": "Preterm very low birth weight (PVLBW) infants", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:34.822184+00:00"}
{"study_id": 76106, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether adding N-Acetylcysteine (NAC) to first-line sequential therapy improves Helicobacter pylori eradication rates.", "results_summary": "The study found numerically higher H. pylori eradication rates in the group receiving NAC (67.3% vs. 58.0%), though the difference was not statistically significant. Adverse event rates and compliance were similar between groups.", "population_specificity": "Patients with Helicobacter pylori infections.", "effective_dosage": "400 mg twice daily for the first 5 days of sequential therapy.", "study_duration": "10 days (NAC administered for the first 5 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.263913+00:00"}
{"study_id": 76107, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) reduces ototoxicity when coadministered with aminoglycosides and to assess the safety of prolonged NAC administration.", "results_summary": "NAC reduced ototoxicity in patients receiving aminoglycosides, with a pooled relative risk of 0.14. Long-term NAC use (\u22656 weeks) was associated with increased gastrointestinal and arthralgic side effects but was generally safe.", "population_specificity": "Patients with end-stage renal failure receiving aminoglycosides and broader populations in long-term NAC studies (N=9988).", "effective_dosage": "Not specified", "study_duration": "\u22656 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.296753+00:00"}
{"study_id": 76109, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether antioxidant supplementation, including N-Acetylcysteine, could reduce the duration of mechanical ventilation in critically ill adults.", "results_summary": "The study found that antioxidant supplementation, including N-Acetylcysteine, significantly reduced the duration of mechanical ventilation, but did not affect all-cause mortality or length of stay in the ICU or hospital.", "population_specificity": "Critically ill adults requiring prolonged mechanical ventilation.", "effective_dosage": "400 mg every 8 hours (in combination with vitamin C and E).", "study_duration": "Duration of mechanical ventilation (specific length not stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:37.191524+00:00"}
{"study_id": 76111, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specifically address N-Acetylcysteine; it focuses on acute liver failure (ALF) complications and management strategies.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its effects.", "population_specificity": "Patients with acute liver failure (ALF).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:39.977455+00:00"}
{"study_id": 76114, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention N-Acetylcysteine or its effects.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its outcomes.", "population_specificity": "Not applicable (N-Acetylcysteine not mentioned).", "effective_dosage": "Not available.", "study_duration": "Not available.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:41.313894+00:00"}
{"study_id": 76113, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether AST or ALT should be used for risk stratification and discontinuation criteria for N-Acetylcysteine treatment following acetaminophen overdose.", "results_summary": "The study found that AST and ALT rise similarly but AST declines faster, suggesting that AST should guide N-Acetylcysteine discontinuation. Using AST could reduce treatment duration by ~24 hours without compromising safety.", "population_specificity": "Adult patients with acetaminophen-induced hepatic injury (peak AST or ALT > 100 IU/L).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:41.812672+00:00"}
{"study_id": 76110, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to determine the effectiveness of N-Acetylcysteine (NAC) in preventing exacerbations of chronic bronchitis and COPD, and to compare the effects of low (\u2264600 mg/day) and high (>600 mg/day) doses.", "results_summary": "NAC significantly reduced exacerbations in chronic bronchitis and COPD patients (relative risk 0.75), with high doses being particularly effective in patients with airway obstruction. NAC was well-tolerated, and adverse reactions were not dose-dependent.", "population_specificity": "4,155 COPD patients (1,933 treated with NAC, 2,222 placebo/controls).", "effective_dosage": "Low dose (\u2264600 mg/day), high dose (>600 mg/day, with \u22651200 mg/day recommended for patients with airway obstruction).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:43.069834+00:00"}
{"study_id": 76112, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy of N-Acetylcysteine (NAC) alone, sodium bicarbonate (SOB) alone, and their combination in preventing contrast-induced nephropathy (CIN) in patients with renal impairment undergoing cardiac catheterization.", "results_summary": "The study found that the combination regimen was not superior to individual NAC or SOB regimens in preventing CIN. NAC alone showed a lower incidence of CIN compared to SOB alone, suggesting it may be more protective.", "population_specificity": "Patients with at least moderate renal impairment (baseline GFR 47.7 \u00b1 13.0 mL/min) undergoing cardiac catheterization with or without percutaneous coronary intervention.", "effective_dosage": "Oral NAC at 1.2g twice daily for 3 days.", "study_duration": "3 days (including pre-, during, and post-procedure administration).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:43.488250+00:00"}
{"study_id": 76116, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential therapeutic utility of N-Acetylcysteine in ameliorating systemic inflammation and neuroinflammation to improve or reverse neuropsychiatric manifestations in hepatic encephalopathy.", "results_summary": "The study suggests that N-Acetylcysteine, among other therapies, may help reduce inflammation and improve neuropsychiatric symptoms in hepatic encephalopathy, based on evidence from patients and animal models.", "population_specificity": "Patients and animal models with acute or chronic liver failure and hepatic encephalopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:43.684202+00:00"}
{"study_id": 76117, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 20, "quality_score": 80, "study_goal": "The researchers aimed to determine if oral N-acetylcysteine (NAC) could reduce inflammation or oxidative stress in asymptomatic individuals with prior asbestos exposure.", "results_summary": "The study found no evidence that NAC supplementation replenished total combined thiols in the blood or reduced inflammatory or oxidative stress indicators. No adverse effects were reported.", "population_specificity": "Asymptomatic individuals with a history of asbestos exposure.", "effective_dosage": "1800 mg orally daily.", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:45.392102+00:00"}
{"study_id": 76115, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-dose intracoronary N-Acetylcysteine (NAC) has antiplatelet effects in patients undergoing primary percutaneous coronary intervention (PCI).", "results_summary": "The study found that NAC did not reduce platelet activation biomarkers within 24 hours post-administration and showed no significant difference in major adverse clinical events compared to placebo at 30 days and 2 years.", "population_specificity": "147 patients undergoing primary PCI, with 100 randomized (50 NAC, 50 placebo).", "effective_dosage": "100 mg/kg bolus, followed by 10 mg\u00b7kg\u207b\u00b9\u00b7h\u207b\u00b9 intracoronary, continued intravenously for 12 hours.", "study_duration": "12 hours (intracoronary + intravenous).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:45.736122+00:00"}
{"study_id": 76118, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review emerging treatments for congenital ichthyosis, including the potential role of N-acetylcysteine in the therapeutic armamentarium.", "results_summary": "The study noted that N-acetylcysteine has been recently added as a treatment option for congenital ichthyosis, though no curative treatments exist. Evidence for therapy remains poor, but N-acetylcysteine is highlighted as a promising addition.", "population_specificity": "Individuals with congenital ichthyosis, including specific subtypes like peeling skin disease, Netherton syndrome, and ichthyosis with confetti.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:48.847357+00:00"}
{"study_id": 76119, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-acetylcysteine as an antidote for acetaminophen overdose and explore mechanisms of cell death to improve intervention strategies.", "results_summary": "N-acetylcysteine is effective in treating early-presenting acetaminophen overdose patients, but late-presenting cases require further intervention development. Mechanistic insights from mouse models largely apply to human hepatocytes.", "population_specificity": "Patients with acetaminophen overdose (early and late presenters) and human hepatocytes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:49.328436+00:00"}
{"study_id": 76122, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the effectiveness of topical N-acetylcysteine as a therapeutic adjunct for patients with concurrent dry eye and Meibomian gland dysfunction.", "results_summary": "The study found that topical N-acetylcysteine can be an effective therapeutic adjunct for patients with concurrent dry eye and Meibomian gland dysfunction, though it was not the primary focus of the abstract.", "population_specificity": "Patients with Meibomian gland dysfunction and concurrent dry eye.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:51.017581+00:00"}
{"study_id": 76121, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "To determine if topical N-acetylcysteine (NAC) reduces protein deposition on contact lenses and improves visual outcomes in patients requiring full-time lens wear.", "results_summary": "Topical NAC reduced protein deposition by 20%, improved visual acuity, and enhanced subjective vision at months 1 and 2. It also decreased ocular surface symptoms and improved lens transparency.", "population_specificity": "Patients with Boston Keratoprosthesis type I or trichiasis from Stevens-Johnson syndrome requiring full-time contact lens wear.", "effective_dosage": "20% NAC (frequency not specified)", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:51.350515+00:00"}
{"study_id": 76120, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to examine the long-term outcomes of N-Acetylcysteine (NAC) in children with trichotillomania, focusing on changes in hairpulling severity and associated symptoms.", "results_summary": "The study found no significant improvement in hairpulling severity over the follow-up period, with participants reporting increased anxiety and depressive symptoms but some improvement in automatic pulling. Older age and greater focused pulling at baseline were associated with poorer long-term prognosis.", "population_specificity": "Children with trichotillomania (30 of 39 original participants from a randomized trial).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Average follow-up of 2.8 \u00b1 0.8 years after baseline evaluation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:52.908711+00:00"}
{"study_id": 76123, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of oral N-Acetylcysteine (NAC) on walking capacity, leg blood flow, inflammatory mediators, and angiogenic markers in patients with intermittent claudication (IC).", "results_summary": "NAC did not improve walking tolerance or leg blood flow in IC patients. It also prevented exercise-induced increases in pro-angiogenic microRNA-126 and blunted changes in other angiogenic mediators.", "population_specificity": "Patients with intermittent claudication (IC) (n=10).", "effective_dosage": "1,800 mg/day for 4 days plus 2,700 mg before the experimental session.", "study_duration": "4 days plus a single pre-session dose.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:52.974319+00:00"}
{"study_id": 76125, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether aerosolized N-acetylcysteine improves airway clearance compared to usual care in hospitalized patients.", "results_summary": "The study found that the routine use of aerosolized N-acetylcysteine to improve airway clearance is not recommended, indicating limited efficacy for this purpose. No high-level evidence supports its use in the studied populations.", "population_specificity": "Hospitalized adult and pediatric patients, including those with neuromuscular disease, respiratory muscle weakness, or impaired cough, and postoperative patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:53.865750+00:00"}
{"study_id": 76124, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine if N-Acetylcysteine added to University of Wisconsin solution could reduce ischemia-reperfusion syndrome and improve short-term outcomes in liver transplant recipients.", "results_summary": "N-Acetylcysteine did not significantly improve ischemia-reperfusion injury or short-term outcomes. Hypotension after portal reperfusion was more common in the experimental group compared to controls.", "population_specificity": "Patients undergoing orthotopic liver transplantation.", "effective_dosage": "Not specified (added to University of Wisconsin solution).", "study_duration": "Not specified (intervention during liver preservation).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:54.324150+00:00"}
{"study_id": 76127, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy, indications, and safety of N-acetylcysteine for off-label use in treating cannabis use disorder (CUD).", "results_summary": "The study found that N-acetylcysteine was one of the few drugs with positive results in double-blind, randomized placebo-controlled trials for CUD, though only 4 out of 13 trials showed positive outcomes. The benefit-risk balance was deemed acceptable for N-acetylcysteine.", "population_specificity": "Individuals with cannabis use disorder (CUD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:58.071508+00:00"}
{"study_id": 76126, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the comparative effectiveness of N-Acetylcysteine (NAC), alone or in combination with corticosteroids, in reducing short-term mortality in patients with severe alcoholic hepatitis.", "results_summary": "The study found that combining NAC with corticosteroids significantly reduced short-term mortality (RR, 0.15; 95% CI, 0.05-0.39), suggesting NAC may enhance the efficacy of corticosteroids. No treatment, including NAC, was effective in reducing medium-term mortality.", "population_specificity": "Adults with severe alcoholic hepatitis (discriminant function \u226532 and/or hepatic encephalopathy).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:59.145127+00:00"}
{"study_id": 76129, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) and other antioxidants could prevent post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).", "results_summary": "NAC was tested in three trials but showed no significant reduction in PEP incidence compared to placebo. The overall antioxidant supplementation, including NAC, did not demonstrate a beneficial effect on PEP prevention.", "population_specificity": "Adults at risk of post-endoscopic retrograde cholangiopancreatography pancreatitis.", "effective_dosage": "Different doses (oral or intravenous, exact amounts not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:00.145376+00:00"}
{"study_id": 76128, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetylcysteine, in combination with other antioxidants and an iron chelator, could improve anemia, iron overload, oxidative stress, and hypercoagulable state in \u03b2-thalassemia/HbE patients.", "results_summary": "The study found that N-acetylcysteine, combined with deferiprone and either curcuminoids or vitamin E, significantly reduced iron load, oxidative stress, and coagulation potential while increasing antioxidant capacity and hemoglobin concentration in responders. The maximum hemoglobin increase was 11% in the curcuminoid group and 10% in the vitamin E group.", "population_specificity": "60 patients with \u03b2-thalassemia/hemoglobin E (HbE), the most common form of \u03b2-thalassemia in Southeast Asia.", "effective_dosage": "Not specified", "study_duration": "10 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:00.750570+00:00"}
{"study_id": 76130, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential of N-acetylcysteine as an immunomodulatory agent to restore immune function and improve survival in patients with acute-on-chronic liver failure (ACLF).", "results_summary": "The abstract suggests N-acetylcysteine has immunomodulatory potential for ACLF patients, but specific efficacy results are not detailed. It is grouped with other drugs that may help restore immune function and prevent secondary infections.", "population_specificity": "Patients with acute-on-chronic liver failure (ACLF) and immuneparesis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:01.602669+00:00"}
{"study_id": 76131, "supplement_id": 1364, "safety_score": "60", "efficacy_score": 75, "quality_score": 80, "study_goal": "To evaluate whether oral N-acetylcysteine (NAC) co-treatment prevents amphotericin B-induced nephrotoxicity and assess its impact on renal function biomarkers.", "results_summary": "NAC co-treatment significantly reduced the odds of amphotericin B nephrotoxicity (OR = 0.286), but no significant differences were found in biomarker accuracy. Adverse reactions were higher in the NAC group.", "population_specificity": "Patients receiving amphotericin B treatment (n = 54).", "effective_dosage": "600 mg oral NAC twice daily.", "study_duration": "Duration of amphotericin B treatment (specific length not stated).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:01.693094+00:00"}
{"study_id": 76132, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine among other pulmonary-specific therapeutic approaches in pediatric acute respiratory distress syndrome.", "results_summary": "The abstract does not provide specific findings on N-Acetylcysteine, only mentioning it as one of the keywords searched. No conclusions or recommendations were made regarding its use.", "population_specificity": "Pediatric patients with acute respiratory distress syndrome (and adult/animal models where pediatric data were lacking).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:02.412902+00:00"}
{"study_id": 76133, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine in restoring GLT-1 expression and correcting manifestations of drug addiction.", "results_summary": "The study found that N-Acetylcysteine shows promise in restoring GLT-1 expression and glutamate uptake, which may help address pre-clinical and clinical manifestations of addiction to substances like cocaine, opioids, ethanol, nicotine, amphetamines, and cannabinoids.", "population_specificity": "Individuals with substance use disorders (pre-clinical and clinical studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:03.900682+00:00"}
{"study_id": 76136, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the effects of N-acetylcysteine on clinical outcomes in animal models with blunt chest trauma.", "results_summary": "N-acetylcysteine, along with methylene blue, was found to improve clinical outcomes in animal models with blunt chest trauma. The study suggests potential benefits in reducing complications post-trauma.", "population_specificity": "Animal models with blunt chest trauma.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:07.028263+00:00"}
{"study_id": 76135, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether differential therapeutic effects of N-Acetylcysteine (NAC) in COPD patients were related to variations in EPHX1 enzyme activity.", "results_summary": "NAC improved FEV1 and SGRQ symptom scores in patients with slow EPHX1 enzyme activity, particularly in mild-to-moderate COPD, but had less impact on severe cases. Yearly exacerbation rates decreased in both groups, though more significantly in the fast/normal EPHX1 activity group.", "population_specificity": "219 patients with COPD, categorized by EPHX1 enzyme activity (extremely slow/slow vs. fast/normal).", "effective_dosage": "600 mg twice daily", "study_duration": "One year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:08.001420+00:00"}
{"study_id": 76137, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the evidence for N-Acetylcysteine (NAC) in treating psychiatric and neurological disorders, focusing on its role in mitigating pathophysiological processes like oxidative stress and neuroinflammation.", "results_summary": "The study found favorable evidence for NAC in treating autism, Alzheimer's disease, addiction disorders, bipolar disorder, and others, while noting insufficient evidence for gambling, methamphetamine addiction, and amyotrophic lateral sclerosis. NAC was deemed safe and tolerable overall.", "population_specificity": "Patients with psychiatric and neurological disorders, including autism, Alzheimer's, addiction disorders, and more.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:09.092219+00:00"}
{"study_id": 76138, "supplement_id": 1364, "safety_score": "60", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of pharmacologic agents, including N-Acetylcysteine, for mucus clearance in hospitalized or postoperative subjects without cystic fibrosis.", "results_summary": "The study found no significant benefit of N-Acetylcysteine on expectoration, pulmonary function, or atelectasis, with minimal effects on sputum volume, weight, or viscosity. Adverse effects like nausea were inconsistently reported, and safety data were incomplete.", "population_specificity": "Hospitalized or postoperative subjects without cystic fibrosis, aged over 12 months.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:09.469262+00:00"}
{"study_id": 76139, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 1, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of N-Acetylcysteine, pirfenidone, and nintedanib in slowing the rate of forced vital capacity decline in patients with idiopathic pulmonary fibrosis.", "results_summary": "The study found that N-Acetylcysteine did not produce a statistically significant slowing in the rate of forced vital capacity decline compared with placebo, unlike pirfenidone and nintedanib. No significant benefit was observed for N-Acetylcysteine in the treatment of idiopathic pulmonary fibrosis.", "population_specificity": "Patients with idiopathic pulmonary fibrosis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:09.713208+00:00"}
{"study_id": 76140, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the protective effects of N-Acetylcysteine (NAC) against insulin resistance and explore its potential mechanisms of action in type-2 diabetes.", "results_summary": "NAC demonstrated anti-oxidative, anti-inflammatory, and anti-apoptotic properties, which may positively impact insulin resistance. It also modulated signaling pathways in insulin target cells and \u03b2 cells, suggesting potential as an adjuvant therapy for type-2 diabetes.", "population_specificity": "Not specified (review of existing literature).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:10.797364+00:00"}
{"study_id": 76141, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine as a potential adjunctive treatment for schizophrenia, focusing on its role as a precursor of glutathione and its anti-inflammatory properties.", "results_summary": "The study suggests N-Acetylcysteine is a promising adjunctive agent for schizophrenia, particularly for treatment-refractory patients, due to its antioxidant and anti-inflammatory effects. However, specific efficacy data or outcomes are not detailed in the abstract.", "population_specificity": "Patients with schizophrenia, particularly treatment-refractory cases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:10.976971+00:00"}
{"study_id": 76142, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) in treating sepsis-induced acute kidney injury (AKI).", "results_summary": "The study found that NAC does not appear to be helpful in the treatment of AKI, based on clinical and experimental data. No significant benefits were reported for NAC in managing sepsis-induced AKI.", "population_specificity": "Human ICU patients and dogs with abdominal sepsis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:11.510124+00:00"}
{"study_id": 76144, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers explored the potential role of N-Acetylcysteine as a therapeutic option for refractory thrombotic thrombocytopenic purpura (TTP).", "results_summary": "The abstract mentions recent evidence for N-Acetylcysteine's potential role in refractory TTP but does not provide specific outcomes or data on its effectiveness.", "population_specificity": "Patients with refractory thrombotic thrombocytopenic purpura (TTP).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:15.525558+00:00"}
{"study_id": 76143, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to investigate clinical management practices for idiopathic pulmonary fibrosis (IPF), including the use of N-Acetylcysteine, following the 2011 international guidelines.", "results_summary": "The study found that 33.7% of IPF patients were administered N-Acetylcysteine, but no specific efficacy or safety outcomes related to its use were reported. The abstract does not provide detailed results on N-Acetylcysteine's effectiveness in treating IPF.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF) in Germany, mean age 68.7\u00b19.4 years, 77.9% males.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:16.629322+00:00"}
{"study_id": 76145, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy of sodium bicarbonate alone versus sodium bicarbonate plus N-Acetylcysteine in preventing contrast-induced nephropathy (CIN).", "results_summary": "The study found that sodium bicarbonate combined with N-Acetylcysteine (OR 0.17) was significantly more effective in preventing CIN than sodium bicarbonate alone (OR 0.71), with a statistically significant result (p=0.024).", "population_specificity": "Patients with pre-existing renal insufficiency undergoing procedures involving contrast agents.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:17.811689+00:00"}
{"study_id": 76146, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether intravenous N-Acetylcysteine could improve high-frequency hearing outcomes, tinnitus, and balance disturbance after stapedotomy surgery.", "results_summary": "N-Acetylcysteine showed no significant effect on high-frequency hearing thresholds, tinnitus, or balance disturbance compared to placebo. Mild side effects (nausea and vomiting) were reported in four treated patients.", "population_specificity": "156 adult patients undergoing stapedotomy at three Swedish university clinics.", "effective_dosage": "150 mg/kg body weight, administered intravenously.", "study_duration": "One hour before surgery (single dose).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:18.229581+00:00"}
{"study_id": 76147, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical effectiveness and cost-effectiveness of N-Acetylcysteine (NAC) for treating idiopathic pulmonary fibrosis (IPF), either alone or in combination with other treatments.", "results_summary": "The study included three trials evaluating NAC (alone or in combination), suggesting some clinical effectiveness, but general recommendations on cost-effectiveness were limited due to evidence constraints. The results were part of a network meta-analysis, but caution was advised in interpreting these findings.", "population_specificity": "Adults over 60 years old with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:18.893081+00:00"}
{"study_id": 76150, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) has clinical efficacy in treating tobacco use disorder (TUD) by reducing cigarette use and cravings.", "results_summary": "NAC significantly reduced daily cigarette use and exhaled carbon monoxide levels compared to placebo, with 47.1% of NAC-treated patients quitting smoking versus 21.4% in the placebo group. NAC also reduced depression scores in TUD patients.", "population_specificity": "34 outpatients with therapy-resistant tobacco use disorder receiving group behavioral therapy.", "effective_dosage": "3 g/day", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:20.062617+00:00"}
{"study_id": 76148, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to analyze the safety and efficacy of N-Acetylcysteine (NAC) in treating non-acetaminophen-induced acute liver failure (NAI-ALF) through a meta-analysis of prospective clinical trials.", "results_summary": "NAC was found to be safe for NAI-ALF and improved survival with native liver and post-transplantation survival, but it did not significantly improve overall survival. Side effects included nausea, vomiting, and diarrhea, with rare occurrences of rashes, fever, and other mild adverse effects.", "population_specificity": "Patients with acute liver failure not caused by acetaminophen poisoning (e.g., alcohol intoxication, hepatitis virus infection, or drug/toxin-related hepatotoxicity).", "effective_dosage": "Not specified (oral or intravenous administration mentioned, but exact dosage not provided).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:21.024430+00:00"}
{"study_id": 76151, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to compare the effectiveness of Fenoldopam versus Saline/Placebo/N-Acetylcysteine in preventing contrast-induced nephropathy (CIN).", "results_summary": "The study found no statistically significant difference in CIN incidence between Fenoldopam and the control group (which included N-Acetylcysteine), suggesting Fenoldopam is no better than Placebo/Saline or NAC for preventing CIN. More studies are needed for conclusive results.", "population_specificity": "Patients at risk of contrast-induced nephropathy (CIN).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:24.149874+00:00"}
{"study_id": 76153, "supplement_id": 1364, "safety_score": "30", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers were evaluating the effectiveness and safety of the combination therapy (prednisone, N-acetylcysteine, and azathioprine) for treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that the combination therapy, including N-acetylcysteine, actually increased mortality in IPF patients, leading to a shift away from this regimen. The abstract highlights newer targeted therapies as more promising alternatives.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:26.262752+00:00"}
{"study_id": 76154, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine as a prophylactic measure to prevent contrast-induced acute kidney injury (CI-AKI).", "results_summary": "The study found uncertainty regarding the efficacy of N-Acetylcysteine in preventing CI-AKI, as it was among several compounds with mixed results in observational and randomized trials. Hydration remained the most reliable strategy, while other compounds, including N-Acetylcysteine, showed inconsistent outcomes.", "population_specificity": "Patients at risk of contrast-induced acute kidney injury (CI-AKI) following contrast media administration.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:26.669628+00:00"}
{"study_id": 76156, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "To determine if N-acetylcysteine is a viable treatment for skin picking in Prader-Willi syndrome.", "results_summary": "The pilot study suggests N-acetylcysteine may be effective for treating skin picking in Prader-Willi syndrome, though further research is needed to confirm these findings.", "population_specificity": "Individuals with Prader-Willi syndrome (specific subtype not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:28.854980+00:00"}
{"study_id": 76149, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of N-Acetylcysteine (NAC) on homocysteine levels, oxidative damage, and iron-related markers in lead-exposed workers.", "results_summary": "NAC administration significantly reduced blood lead levels, decreased homocysteine and protein carbonyl groups, and elevated protein thiol groups in a dose-dependent manner, indicating reduced oxidative stress and improved biochemical markers.", "population_specificity": "Male workers exposed to lead (n = 171).", "effective_dosage": "1 \u00d7 200 mg, 2 \u00d7 200 mg, or 2 \u00d7 400 mg daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:29.082026+00:00"}
{"study_id": 76157, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) improves symptoms and pulmonary function in patients with severe COPD exacerbation and increased sputum production.", "results_summary": "NAC did not show any significant difference in symptom improvement, pulmonary function, or exacerbation rates compared to placebo, despite both groups showing some improvement. The study concluded that NAC has no beneficial effect on clinical outcomes in this population.", "population_specificity": "Patients with severe COPD and increased sputum production, hospitalized for an exacerbation.", "effective_dosage": "200 mg three times daily (tid)", "study_duration": "Not specified (follow-up period was 6 months)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:29.818552+00:00"}
{"study_id": 76155, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 30, "quality_score": 70, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alone or combined with vitamin C, could protect against delayed graft function (DGF) in kidney transplant recipients by reducing biomarkers NGAL and IL-18.", "results_summary": "The study found no significant differences in DGF prevalence, duration, or biomarker levels between groups receiving NAC, NAC plus vitamin C, or standard care. NAC was deemed safe but showed no significant beneficial effects on DGF biomarkers or kidney function.", "population_specificity": "Living donor kidney transplant recipients.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Urine samples were taken 4 and 24 hours post-transplantation; follow-up at 30 and 60 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:30.289955+00:00"}
{"study_id": 76158, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effectiveness and safety of N-acetylcysteine (NAC) as an adjunct to risperidone in treating autistic disorders (ADs) in children.", "results_summary": "The study found that NAC significantly reduced irritability and hyperactivity/noncompliance scores compared to placebo when combined with risperidone. The effects were statistically significant by week 10.", "population_specificity": "Children aged 4-12 years with autistic disorders and an ABC-C Irritability subscale score >12.", "effective_dosage": "600-900 mg/d of NAC, titrated risperidone (1-2.0 mg/d).", "study_duration": "10 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:33.393014+00:00"}
{"study_id": 76160, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the protective effects of N-Acetylcysteine (NAC) on intestinal health and explore its molecular mechanisms of action.", "results_summary": "NAC was found to reduce inflammation, alleviate oxidative stress, improve energy status, and ameliorate tissue damage in the intestines of lipopolysaccharide-challenged piglets. Additionally, dietary NAC supplementation improved acetic acid-induced colitis in a porcine model, with effects linked to intestinal cell signaling pathways.", "population_specificity": "Lipopolysaccharide-challenged piglets and a porcine model of acetic acid-induced colitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:35.279457+00:00"}
{"study_id": 76159, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could suppress methamphetamine (METH) craving in dependent individuals.", "results_summary": "NAC significantly reduced METH craving scores compared to placebo, with a statistically significant main effect (P < 0.001). Only mild side effects were reported, with no difference in frequency between NAC and placebo groups.", "population_specificity": "32 METH-dependent volunteers (23 completed the study).", "effective_dosage": "1200 mg/day.", "study_duration": "Two four-week sessions with a three-day washout period in between.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:35.623416+00:00"}
{"study_id": 76161, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 68, "study_goal": "The researchers aimed to compare the antioxidant effects of N-acetylcysteine (NAC), melatonin, and their combination in sickle cell erythrocytes.", "results_summary": "NAC and melatonin treatments neutralized increased lipid peroxidation levels caused by incubation. Combined treatment showed a modulating effect on GPx and SOD activities, with a dose-dependent antioxidant effect observed for melatonin and combined treatments on MDA levels and SOD activity.", "population_specificity": "Sickle cell erythrocytes in vitro", "effective_dosage": "100 pm, 100 nm, and 100 \u03bcm concentrations", "study_duration": "1 hour", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:37.229435+00:00"}
{"study_id": 76162, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether inhaled N-acetylcysteine monotherapy benefits patients with early-stage idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that inhaled N-acetylcysteine monotherapy was beneficial for patients with early IPF (stage I/II) who showed no desaturation on exertion. It suggests N-acetylcysteine is suitable for early IPF, while pirfenidone is more appropriate for advanced cases.", "population_specificity": "Patients with early-stage idiopathic pulmonary fibrosis (IPF stage I/II, no desaturation on exertion).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:37.632922+00:00"}
{"study_id": 76164, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to assess the effectiveness and safety of N-acetylcysteine as a glutamatergic modulator for reducing cannabis withdrawal symptoms and promoting cessation or reduction of cannabis use.", "results_summary": "The study found insufficient data for quantitative estimates of N-acetylcysteine's effectiveness, but suggested it may be worth further investigation. No significant adverse effects or strong efficacy outcomes were reported.", "population_specificity": "Cannabis-dependent individuals or those likely to be dependent, predominantly male (approximately 80%) with an average age of 33 years.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:38.386883+00:00"}
{"study_id": 76163, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to review the role of N-Acetylcysteine in preventing progression to acute liver failure (ALF) following acetaminophen overdose and explore emerging treatments for ALF.", "results_summary": "N-Acetylcysteine effectively reduces progression to ALF if administered early after acute acetaminophen overdose, but liver transplantation remains the primary life-saving intervention once ALF develops. The abstract highlights the need for early diagnosis and novel bridging therapies for ALF patients.", "population_specificity": "Patients with acetaminophen-induced acute liver failure or at risk of developing it.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:38.528469+00:00"}
{"study_id": 76152, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety and efficacy of N-Acetylcysteine (NAC) in preventing noise-induced hearing loss (NIHL) in military personnel during weapons training.", "results_summary": "The study found no significant difference in the primary outcome (rate of threshold shifts) between NAC and placebo groups, though secondary outcomes and post-hoc analyses suggested some benefit for NAC, particularly when considering handedness. Adverse event rates were similar between groups, indicating NAC was well-tolerated.", "population_specificity": "Military personnel at risk for noise-induced hearing loss during weapons training.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:40.009243+00:00"}
{"study_id": 76165, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to assess N-Acetylcysteine as a potential preventive strategy for cardiac surgery-associated acute kidney injury (CSA-AKI).", "results_summary": "The abstract mentions N-Acetylcysteine as part of prevention strategies for CSA-AKI but does not provide specific efficacy results, suggesting mixed or inconclusive findings.", "population_specificity": "Patients undergoing cardiac surgery at risk of acute kidney injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:41.847719+00:00"}
{"study_id": 76167, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review N-Acetylcysteine as a potential neurotherapeutic target for cognitive enhancement in major depressive disorder (MDD).", "results_summary": "The abstract identifies N-Acetylcysteine as a promising neurotherapeutic target for cognitive dysfunction in MDD, but notes that no randomized controlled trials (RCTs) have been performed to confirm its efficacy.", "population_specificity": "Patients with major depressive disorder (MDD), particularly those with cognitive dysfunction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:43.414751+00:00"}
{"study_id": 76166, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of N-acetylcysteine (NAC) on follicular fluid parameters, oocyte quality, and embryo quality in women with PCOS undergoing ICSI.", "results_summary": "NAC significantly reduced the number of immature and abnormal oocytes, increased good-quality embryos, and lowered malondialdehyde and leptin levels compared to placebo. It also improved insulin and LH levels, demonstrating efficacy comparable to metformin.", "population_specificity": "60 Iranian women with PCOS (aged 25-35 years) undergoing intracytoplasmic sperm injection (ICSI).", "effective_dosage": "1800mg/day NAC", "study_duration": "6 weeks (from the 3rd day of the previous cycle until oocyte aspiration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:44.574484+00:00"}
{"study_id": 76169, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical and cost-effectiveness of N-Acetylcysteine (NAC) alone or in combination for treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that NAC triple therapy and inhaled NAC showed increased survival compared to best supportive care, but only inhaled NAC was cost-effective at current willingness-to-pay thresholds, though its clinical effectiveness was uncertain. The network meta-analysis did not show statistically significant improvements for NAC treatments.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:45.629985+00:00"}
{"study_id": 76171, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to review the available literature on pharmacotherapy for trichotillomania, including preliminary evidence for N-acetylcysteine.", "results_summary": "The abstract mentions preliminary evidence for N-acetylcysteine in treating trichotillomania, but larger trials are needed to confirm its efficacy. Most trials for other pharmacotherapies were negative.", "population_specificity": "Adults or children with trichotillomania (hair-pulling disorder).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:45.726328+00:00"}
{"study_id": 76168, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine whether oral N-acetylcysteine (NAC) supplementation could reduce oxidative stress and improve lung function in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.", "results_summary": "NAC treatment significantly increased plasma levels of ascorbic acid and decreased dehydroascorbate, indicating reduced oxidative stress. A non-significant improvement in lung function was also observed in the NAC group compared to controls.", "population_specificity": "21 cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection (11 in NAC group, 10 controls).", "effective_dosage": "2400 mg/day (divided into two doses of 1200 mg each).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:46.250938+00:00"}
{"study_id": 76170, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize current evidence on the role of glutathione (GSH) redox imbalance in brain disorders and evaluate the potential therapeutic effects of N-acetylcysteine in increasing GSH levels to alleviate oxidative stress-associated damage.", "results_summary": "The study found that N-acetylcysteine, along with other agents, can increase GSH levels in the brain, potentially alleviating oxidative stress-associated damage and improving behavior in individuals with neuropsychiatric and neurodegenerative disorders.", "population_specificity": "Individuals with neuropsychiatric and neurodegenerative disorders (e.g., autism, schizophrenia, bipolar disorder, Alzheimer's disease, Parkinson's disease).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:49.031714+00:00"}
{"study_id": 76173, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) as an adjuvant treatment for eradicating mature bacterial biofilms and inhibiting new biofilm formation.", "results_summary": "The study found that NAC, when combined with antibiotics, significantly improved their permeability into biofilms, overcoming resistance issues. The results suggested NAC has an excellent safety and efficacy profile for treating biofilm-related infections.", "population_specificity": "Patients with biofilm-related infections in various body districts, such as the vaginal cavity.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:49.804219+00:00"}
{"study_id": 76172, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness of N-Acetylcysteine (NAC) combined with Sodium Chloride (NaCl) against other treatments (Na bicarbonate and NaCl alone) in preventing contrast-induced nephropathy in high-risk patients undergoing coronary angiography.", "results_summary": "The study found that NAC combined with NaCl did not show a significant increase in creatinine (Cr) levels 48 hours post-intervention, unlike the NaCl-only group. However, the incidence of contrast-induced nephropathy was not statistically significant between all groups, suggesting NAC's efficacy may be limited in this context.", "population_specificity": "High-risk patients undergoing coronary angiography with at least one risk factor (congestive heart failure, diabetes mellitus, age >65 years, or renal failure).", "effective_dosage": "Not specified", "study_duration": "48 hours post-angiography", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:50.170619+00:00"}
{"study_id": 76174, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the pharmacodynamic effects of N-Acetylcysteine (NAC) on the international normalized ratio (INR) in paracetamol overdose cases.", "results_summary": "The study found that both paracetamol and NAC contributed to the elevation of INR, with NAC showing a measurable pharmacological effect. Simulated paracetamol overdoses with NAC administration resulted in INR values that reached or exceeded the reference range.", "population_specificity": "Patients with paracetamol and psychotropic overdoses (median age 22 years, range 13-71 years).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:51.805278+00:00"}
{"study_id": 76177, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 65, "quality_score": 85, "study_goal": "To evaluate the effects of oral N-acetylcysteine (NAC) on reducing inflammation and improving lung function in individuals with cystic fibrosis (CF).", "results_summary": "NAC recipients maintained or slightly improved lung function (FEV1 and FEF25-75%) compared to placebo recipients, who experienced a decline. However, NAC did not significantly affect sputum human neutrophil elastase (HNE) activity or other biomarkers of neutrophilic inflammation.", "population_specificity": "70 subjects with cystic fibrosis.", "effective_dosage": "Oral NAC thrice daily (specific dosage not mentioned).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:54.109871+00:00"}
{"study_id": 76176, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the protective effects of N-acetylcysteine (NAC) and N-acetylcysteineamide (NACA) against acetaminophen (APAP)-induced hepatotoxicity in a human-relevant in vitro system.", "results_summary": "Both NAC and NACA protected against APAP-induced hepatotoxicity by restoring glutathione levels, scavenging reactive oxygen species, inhibiting lipid peroxidation, and preserving mitochondrial function, but NACA was more effective than NAC in combating oxidative stress and cellular damage.", "population_specificity": "HepaRG cells (a human-relevant in vitro liver cell model)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:54.218984+00:00"}
{"study_id": 76178, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effects of N-acetylcysteine (NAC) on oxidative stress and DNA damage in children with \u03b2-thalassemia major (\u03b2-TM).", "results_summary": "NAC significantly reduced oxidative stress (measured by TOS and OSI), increased antioxidant capacity (TAC), and decreased DNA damage in children with \u03b2-TM. It also improved pre-transfusion hemoglobin levels.", "population_specificity": "Children with transfusion-dependent \u03b2-thalassemia major (\u03b2-TM).", "effective_dosage": "10 mg/kg/day", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:54.375177+00:00"}
{"study_id": 76179, "supplement_id": 1364, "safety_score": "30", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of N-Acetylcysteine (NAC) as part of a triple-therapy regimen for treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that triple-therapy with NAC, azathioprine, and prednisone resulted in increased mortality, and single-agent NAC demonstrated a lack of efficacy in treating IPF.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:56.858707+00:00"}
{"study_id": 76180, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of N-acetylcysteine (NAC) versus placebo, combined with contingency management, for cannabis cessation in adults.", "results_summary": "The study is ongoing, but previous research in adolescents showed NAC increased odds of abstinence compared to placebo. The current study seeks to replicate these findings in adults.", "population_specificity": "Treatment-seeking cannabis-dependent adults aged 18-50.", "effective_dosage": "1200 mg twice daily.", "study_duration": "12 weeks with a 4-week follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:58.785672+00:00"}
{"study_id": 76181, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to explore the role of N-Acetylcysteine in impairing the cytotoxicity of Taurolidine by reducing oxidative stress in tumor cells.", "results_summary": "The study found that N-Acetylcysteine reduces the cytotoxic effects of Taurolidine on tumor cells by mitigating oxidative stress, suggesting it counteracts Taurolidine's antineoplastic activity. No direct efficacy of N-Acetylcysteine as a standalone treatment was assessed.", "population_specificity": "Tumor cells (in vitro and in vivo), including tumor stem cells.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Impairs Taurolidine's cytotoxicity; effectiveness is reduced by N-Acetylcysteine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:59.857157+00:00"}
{"study_id": 76182, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-acetylcysteine (NAC) could prevent nonthyroidal illness syndrome (NTIS) in patients with acute myocardial infarction by mitigating oxidative stress.", "results_summary": "NAC prevented the decrease in T3 levels and reduced elevated rT3 levels in patients with acute myocardial infarction, while placebo did not. NAC also corrected oxidative imbalances, suggesting its role in NTIS pathophysiology.", "population_specificity": "Patients admitted to emergency and intensive care units of two tertiary hospitals in southern Brazil with acute myocardial infarction.", "effective_dosage": "Not specified", "study_duration": "48 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:00.976473+00:00"}
{"study_id": 76184, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could improve the phenotypic conditions of Fanconi anemia (FA) by addressing altered red-ox metabolism in FANCA lymphocytes.", "results_summary": "NAC failed to revert all characteristics of the FA phenotype, and its effects were not superimposable with resveratrol, suggesting limited efficacy in this context. The study highlights the need for caution regarding the biological effects of antioxidant treatments in FA.", "population_specificity": "FANCA lymphocytes from individuals with Fanconi anemia (FA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:02.973821+00:00"}
{"study_id": 76183, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine (NAC) in treating acetaminophen poisoning and determine when extracorporeal treatments (ECTR) might be necessary.", "results_summary": "The study found that NAC is the mainstay of treatment for acetaminophen poisoning and that ECTR is generally not needed except in cases of excessively large overdoses with signs of mitochondrial dysfunction. The workgroup concluded that intermittent hemodialysis is the preferred ECTR modality when required.", "population_specificity": "Patients with acetaminophen poisoning, including those with severe overdoses and mitochondrial dysfunction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:04.402811+00:00"}
{"study_id": 76185, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the dose-dependent effects of N-Acetylcysteine (NAC) on lung function and exacerbation rates in COPD patients, particularly focusing on its antioxidant and anti-inflammatory properties.", "results_summary": "High-dose NAC (1,200 mg daily) reduced exacerbations in COPD patients, especially in moderately severe cases and high-risk individuals, but showed no significant effect on symptoms or quality of life. Earlier studies (BRONCUS) found limited benefits, only reducing exacerbations in an \"inhaled steroid-na\u00efve\" subgroup.", "population_specificity": "Patients with chronic obstructive pulmonary disease (COPD), particularly those with moderately severe disease or high exacerbation risk, primarily from Chinese trials.", "effective_dosage": "1,200 mg daily (high-dose)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:04.462205+00:00"}
{"study_id": 76186, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the course of disease, adverse events, and compliance in IPF patients treated with pirfenidone, including those receiving concomitant N-acetylcysteine (NAC).", "results_summary": "The study found that 34% of patients received pirfenidone combined with NAC and/or corticosteroids, with adverse events and treatment discontinuation more frequent in this group. No specific efficacy or safety data for NAC alone were reported.", "population_specificity": "Patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Mean follow-up of 11 (\u00b17) months", "interactions": "Concomitant use with corticosteroids was noted, but no specific NAC interactions were detailed.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:05.525776+00:00"}
{"study_id": 76187, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could protect cochlear function and reduce oxidative stress in patients with amikacin-related ototoxicity during peritoneal dialysis-related peritonitis treatment.", "results_summary": "NAC protected cochlear function, particularly at higher frequencies, and improved antioxidant status compared to the placebo group, with significant effects observed by the fourth week. NAC was found to be safe and effective in mitigating amikacin-related ototoxicity.", "population_specificity": "Patients with first-time peritoneal dialysis-related peritonitis receiving empirical amikacin treatment.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Measurements were taken before treatment, 1 week after, and 4 weeks after treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:08.309330+00:00"}
{"study_id": 76188, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the pharmacokinetics and placental transfer of intravenous N-Acetylcysteine (NAC) in mothers with chorioamnionitis and its pharmacokinetics in their infants.", "results_summary": "Maternal clearance of NAC was rapid, with umbilical cord concentrations often exceeding maternal levels. Neonatal pharmacokinetics showed shorter elimination half-life and greater clearance in near-term infants compared to preterm infants.", "population_specificity": "Pregnant women \u226524 weeks' gestation with chorioamnionitis and their infants (including preterm and near-term).", "effective_dosage": "Maternal: 100 mg/kg/dose every 6 hours until delivery; Neonatal: 12.5-25 mg/kg/dose every 12 hours for 5 doses.", "study_duration": "Maternal: Until delivery; Neonatal: 5 doses over 60 hours.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:10.014326+00:00"}
{"study_id": 76189, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety and feasibility of co-administering N-Acetylcysteine (NAC) and varenicline (VAR) in nicotine-dependent individuals.", "results_summary": "The study found that co-administration of NAC and VAR was safe, with most adverse events being mild (88%). Medication adherence was excellent (98%), and exploratory analyses showed reductions in cigarettes per day, though abstinence rates remained low.", "population_specificity": "Daily cigarette smokers not necessarily seeking treatment (n=19).", "effective_dosage": "1200 mg NAC twice daily.", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:10.044176+00:00"}
{"study_id": 76192, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to review the effectiveness of glutamatergic drugs, including N-Acetylcysteine, in treating gambling disorder and related symptoms.", "results_summary": "The study suggests that N-Acetylcysteine and other glutamatergic drugs show promise in modulating gambling behaviors and associated clinical dimensions like craving and cognitive symptoms, though further research is needed.", "population_specificity": "Patients with pathological gambling or gambling disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:12.010575+00:00"}
{"study_id": 76190, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy of N-acetylcysteine (NAC) in preventing and treating sulfur mustard-induced acute and chronic pulmonary toxicities.", "results_summary": "NAC was found effective in managing sulfur mustard-induced acute lung injury via antioxidant and anti-inflammatory mechanisms, and it improved clinical outcomes in patients with bronchiolitis obliterans, though mechanisms remain undetermined.", "population_specificity": "Individuals exposed to sulfur mustard, including those with acute lung injury and chronic bronchiolitis obliterans.", "effective_dosage": "600-1800 mg/day (oral), with variations in administration routes (intravenous, intraperitoneal, intra-tracheal).", "study_duration": "4-6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:12.294914+00:00"}
{"study_id": 76175, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alone or in combination with other nutraceuticals, could improve depressive symptoms in bipolar disorder by targeting oxidative stress and mitochondrial dysfunction.", "results_summary": "The study measured changes in depression ratings, functioning, and quality of life, but specific results for NAC's efficacy were not detailed in the abstract. Biological samples were collected to explore biochemical changes post-treatment.", "population_specificity": "Adults diagnosed with bipolar disorder currently experiencing a depressive episode.", "effective_dosage": "Not specified", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:12.525606+00:00"}
{"study_id": 76193, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to investigate the relationship between metabolic diseases and endothelial dysfunction, and explore the potential therapeutic use of N-Acetylcysteine in these conditions.", "results_summary": "The abstract suggests that endothelial dysfunction plays a key role in metabolic diseases and implies that N-Acetylcysteine may have therapeutic benefits, but specific results are not detailed.", "population_specificity": "Not specified (general focus on metabolic diseases and endothelial dysfunction).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:13.419319+00:00"}
{"study_id": 76191, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of N-Acetylcysteine (NAC) plus saline, sodium bicarbonate plus saline, and saline alone in preventing contrast-induced nephropathy (CIN) in emergency department patients at moderate or high risk.", "results_summary": "The study found no significant difference in CIN prevention between NAC plus saline, sodium bicarbonate plus saline, and saline alone, with 19.4%, 11.1%, and 14.2% of patients developing CIN, respectively.", "population_specificity": "Adult emergency department patients at moderate or high risk of CIN requiring contrast-enhanced CT.", "effective_dosage": "150 mg/kg NAC in 1000 mL of 0.9% NaCl, infused at 350 mL/hr for 3 hours.", "study_duration": "3 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:14.521362+00:00"}
{"study_id": 76195, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as a preventive or early intervention therapy for schizophrenia by targeting redox, neuroimmune, and glutamatergic dysregulation.", "results_summary": "The study suggests N-Acetylcysteine, due to its antioxidant, anti-inflammatory, and glutamatergic regulatory properties, may help address neurodevelopmental anomalies linked to schizophrenia, potentially improving cognitive and behavioral outcomes.", "population_specificity": "Ultra-high risk patients or individuals in the early stages of schizophrenia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:18.163133+00:00"}
{"study_id": 76194, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of N-Acetylcysteine (NAC) as an adjunctive therapy for Major Depressive Disorder (MDD), focusing on its effects on depressive symptoms and functional outcomes.", "results_summary": "The study found no significant difference between NAC and placebo on the primary outcome (MADRS) at week 12, but NAC showed benefits in functional outcomes (LIFE-RIFT) and secondary measures at week 16, particularly in participants with severe depression (MADRS \u2265 25). Adverse events, mainly gastrointestinal and musculoskeletal, were more frequent in the NAC group.", "population_specificity": "Adults with a current episode of Major Depressive Disorder (MDD) diagnosed by DSM-IV-TR criteria (N = 252).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks of treatment, with follow-up to 16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:18.984902+00:00"}
{"study_id": 76197, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine as a novel pharmacological treatment option for early-onset schizophrenia (EOS).", "results_summary": "The abstract mentions N-Acetylcysteine as one of the new pharmacological options under evaluation for EOS, but no specific results regarding its effects are provided.", "population_specificity": "Early-onset schizophrenia (EOS) patients.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:19.345703+00:00"}
{"study_id": 76196, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess whether combination therapy with oral cysteamine bitartrate and N-acetylcysteine could benefit patients with infantile neuronal ceroid lipofuscinosis by delaying disease progression and improving symptoms.", "results_summary": "The study found that the combination therapy delayed the onset of isoelectric EEG, depleted granular osmiophilic deposits (GRODs) in leukocytes, and improved subjective symptoms like irritability and alertness in most patients, though no new developmental skills were acquired.", "population_specificity": "Children aged 6 months to 3 years with infantile neuronal ceroid lipofuscinosis and specific PPT1 mutations.", "effective_dosage": "60 mg/kg per day of N-acetylcysteine.", "study_duration": "8 to 75 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:19.400434+00:00"}
{"study_id": 76198, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alone or combined with hydration solutions, could reduce the incidence of contrast-induced nephropathy (CIN) after percutaneous coronary intervention.", "results_summary": "The study found no statistically significant reduction in CIN incidence with NAC, either alone or combined with hydration solutions. However, in high-risk patients (diabetes and/or renal dysfunction), SB + NAC might be slightly superior to isotonic crystalloid solutions.", "population_specificity": "Patients admitted for percutaneous coronary intervention, including those with diabetes and/or renal dysfunction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:20.848393+00:00"}
{"study_id": 76199, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine (NAC) as a potential therapeutic drug for schizophrenia by examining its role in modulating NMDA receptor function and addressing oxidative stress.", "results_summary": "The study reviewed NAC as a precursor of glutathione (GSH) and an activator of the cystine-glutamate antiporter, suggesting its potential in addressing NMDA receptor dysfunction and oxidative stress in schizophrenia. Clinical findings for NAC were outlined alongside other NMDA receptor modulators, but specific efficacy data were not detailed.", "population_specificity": "Schizophrenia patients (preclinical and clinical studies reviewed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:21.401166+00:00"}
{"study_id": 76200, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of N-Acetylcysteine (NAC) on non-enzymatic defense systems and oxidative stress in lead-exposed workers.", "results_summary": "NAC administration (400 mg, 800 mg) significantly reduced lipid hydroperoxides (LHP) and showed a tendency to lower conjugated dienes (CD), while increasing alpha-tocopherol levels. Uric acid levels decreased only with the 200 mg dose, and NAC did not significantly affect bilirubin or albumin but showed a trend toward higher FRAP values.", "population_specificity": "Male employees exposed to lead in their workplace.", "effective_dosage": "200 mg, 400 mg, and 800 mg for 12 weeks.", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:23.353714+00:00"}
{"study_id": 76201, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of nebulized N-acetylcysteine in treating acute bronchiolitis in children compared to salbutamol.", "results_summary": "N-acetylcysteine showed better improvement in clinical severity scores by the third and fifth days of treatment and resulted in shorter hospitalization durations compared to salbutamol.", "population_specificity": "Children aged 2 months to 24 months diagnosed with acute viral bronchiolitis.", "effective_dosage": "Not specified", "study_duration": "Treatment duration was assessed up to 5 days, with hospitalization lasting an average of 4.36 days for the N-acetylcysteine group.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:23.659483+00:00"}
{"study_id": 76202, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of N-Acetylcysteine on mortality in adult patients with acute respiratory distress syndrome (ARDS).", "results_summary": "The study found no effect of N-Acetylcysteine on mortality in ARDS patients, based on meta-analysis of trials. The results were consistent with other pharmacologic therapies that showed no benefit.", "population_specificity": "Adult patients with ARDS (using authors' definitions).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:25.589925+00:00"}
{"study_id": 76203, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the severity and prevalence of adverse side effects of N-acetylcysteine in treating paracetamol intoxication and assess its implications for treatment guidelines.", "results_summary": "The study found that N-acetylcysteine is effective in treating paracetamol intoxication but noted potential adverse effects at low plasma concentrations, while higher concentrations without treatment could lead to severe morbidity and mortality. The conclusion supports continued use of existing guidelines for N-acetylcysteine administration.", "population_specificity": "Patients with paracetamol intoxication.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:27.219119+00:00"}
{"study_id": 76204, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 85, "study_goal": "The researchers aimed to determine whether NKX3.1 genetic variants modify the effect of antioxidant administration (including N-Acetylcysteine) on prostate cancer risk.", "results_summary": "The study found that NKX3.1 genetic variants combined with selenium or vitamin E administration increased prostate cancer risk, suggesting that N-Acetylcysteine's effects may vary based on genetic background.", "population_specificity": "Men in the SELECT biomarker case-cohort substudy (1,866 cases; 3,135 non-cases).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:27.494946+00:00"}
{"study_id": 76205, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effect of high-dose NAC (600 mg bid) between high-risk and low-risk Chinese patients with COPD to determine which group benefits most.", "results_summary": "High-dose NAC significantly reduced exacerbation frequency, prolonged time to first exacerbation, and increased the probability of being exacerbation-free at 1 year in high-risk COPD patients, but these benefits were not significant in low-risk patients.", "population_specificity": "Chinese patients with spirometry-confirmed stable COPD (93.2% men, mean age 70.8 years).", "effective_dosage": "600 mg twice daily (bid)", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:27.842906+00:00"}
{"study_id": 76207, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the role of oxidative stress in COPD and evaluate the clinical and experimental evidence for using N-acetylcysteine (NAC) as an adjunct therapy.", "results_summary": "NAC may reduce COPD exacerbation rates and improve small airways function, likely due to its mucolytic and antioxidant effects, with potential modulation of bronchial inflammation.", "population_specificity": "Subjects with chronic obstructive pulmonary disease (COPD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:28.813183+00:00"}
{"study_id": 76206, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-acetylcysteine, as an antioxidant, could synergistically enhance the chemotactic activity of S100A4 on mesenchymal stromal cells (MSCs) in the tumor microenvironment.", "results_summary": "N-acetylcysteine, like other antioxidants, enhanced the chemotactic activity of S100A4 on MSCs in a synergistic manner, suggesting its role in promoting MSC-associated immunoregulation. However, it did not alter MSC survival or differentiation.", "population_specificity": "Mesenchymal stromal cells (MSCs) in the tumor microenvironment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:29.471313+00:00"}
{"study_id": 76208, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers aimed to explore the reversibility of fibrosis and fibroblast-to-myofibroblast differentiation, including potential therapeutic compounds like N-Acetylcysteine.", "results_summary": "The abstract discusses the potential reversibility of fibrosis and myofibroblast differentiation, mentioning compounds that could reverse these processes, but does not specify results for N-Acetylcysteine.", "population_specificity": "Not specified (general discussion of fibrotic disorders).", "effective_dosage": "Not provided", "study_duration": "Not provided", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:30.632406+00:00"}
{"study_id": 76209, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could influence cigarette smoking outcomes during a cannabis cessation trial in adolescents.", "results_summary": "The study found no change in cigarette smoking among participants receiving NAC or placebo during the eight-week treatment. There was no evidence of compensatory cigarette smoking, and being a cigarette smoker did not significantly influence NAC's effects on cannabis abstinence.", "population_specificity": "Cannabis-dependent adolescents aged 15-21 (n=116), including daily and non-daily cigarette smokers.", "effective_dosage": "1200 mg twice daily (bid)", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:32.754668+00:00"}
{"study_id": 76210, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alone or combined with sodium bicarbonate, could reduce the rate of contrast-induced nephropathy (CIN) in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.", "results_summary": "NAC alone or combined with sodium bicarbonate did not significantly reduce the rate of acute CIN compared to hydration alone. However, the combination of NAC and sodium bicarbonate showed a potential benefit in reducing renal dysfunction after 30 days.", "population_specificity": "Patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, excluding those in cardiogenic shock.", "effective_dosage": "Not specified", "study_duration": "Intervention duration not explicitly stated; outcomes measured within 3 days and at 30 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:35.952251+00:00"}
{"study_id": 76211, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine if intravenous N-Acetylcysteine (NAC) could prevent acute kidney injury (AKI) in allogeneic hematopoietic stem cell transplantation patients.", "results_summary": "The study found no significant difference in AKI occurrence between NAC and placebo groups (18% vs. 15%, p = 0.73), nor in secondary outcomes like uNGAL levels. Transplant-related outcomes were similar, and adverse reactions were not significantly different, though three NAC recipients dropped out due to intolerance.", "population_specificity": "Allogeneic hematopoietic stem cell transplantation patients.", "effective_dosage": "100 mg/kg/day as intermittent intravenous infusion.", "study_duration": "From day -6 to day +15 (21 days total).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:36.304350+00:00"}
{"study_id": 201438, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the effectiveness of omega-3 fatty acid supplementation as a pharmacologic treatment for postpartum depression.", "results_summary": "The study found no evident effectiveness of omega-3 fatty acids in treating postpartum depression, with significant methodological limitations noted. Therapeutic effects were documented for prescription antidepressants and hormone supplementation, but not for omega-3s.", "population_specificity": "Women diagnosed with depression during the 12 months after delivery (postpartum depression).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:43.952846+00:00"}
{"study_id": 201443, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine if red blood cell (RBC) and white blood cell (WBC) fatty acid composition could accurately reflect omega-3 fatty acid supplementation compliance and correlate with biochemical changes in WBCs.", "results_summary": "The study found that omega-3 fatty acid levels increased in both RBCs and WBCs after supplementation, with RBCs showing a linear, dose-responsive increase, while WBCs exhibited a non-linear response. The magnitude of increase differed between cell types, suggesting RBC analysis is useful for compliance but WBC analysis is needed to correlate with biochemical changes.", "population_specificity": "Not specified (human clinical trial, but exact population details not provided in abstract).", "effective_dosage": "Three doses of omega-3 fatty acid supplement (exact amounts not specified in abstract).", "study_duration": "Not specified in abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:46.919574+00:00"}
{"study_id": 201439, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether omega-3 fatty acid supplementation could improve myocardial performance and reduce mortality and hospitalizations in heart failure patients.", "results_summary": "The study found that omega-3 fatty acid supplementation showed a modest decrease in mortality and hospitalizations in patients with New York Heart Association class II-IV heart failure, though larger trials are needed for conclusive evidence.", "population_specificity": "Patients with New York Heart Association class II-IV heart failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:47.085959+00:00"}
{"study_id": 201441, "supplement_id": 1396, "safety_score": "85", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the cardiovascular effects of omega-3 fatty acids, focusing on all-cause mortality and coronary restenosis prevention, while assessing potential sources of heterogeneity in results.", "results_summary": "Omega-3 fatty acids were not significantly associated with reduced mortality or restenosis, though there was a high probability of modest benefit. Larger and longer studies showed smaller benefits, suggesting possible bias.", "population_specificity": "High-risk cardiovascular patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:47.139897+00:00"}
{"study_id": 201444, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to establish the range of PUFA levels in typically developing school children and explore associations between omega-3 fatty acid levels, behaviour, and cognitive performance.", "results_summary": "Higher omega-3 levels were associated with decreased inattention, hyperactivity, emotional and conduct difficulties, and increased prosocial behaviour, but no associations were found with reading, spelling, or intelligence measures.", "population_specificity": "411 typically developing school-aged children.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:47.374543+00:00"}
{"study_id": 201440, "supplement_id": 1396, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of dietary supplementation with omega-3 fatty acids on symptom severity in patients with borderline personality disorder (BPD).", "results_summary": "The study found suggestive evidence supporting the use of omega-3 fatty acids for BPD, though most effect estimates were based on single studies and require replication. No significant adverse effects were reported for omega-3 fatty acids.", "population_specificity": "Patients diagnosed with borderline personality disorder (BPD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:47.585968+00:00"}
{"study_id": 201442, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of omega-3 fatty acids, particularly DHA, in brain health and their potential therapeutic effects in Alzheimer's disease (AD).", "results_summary": "The study found that while omega-3 fatty acids are essential for brain function and low DHA levels are associated with cognitive decline, clinical trials failed to demonstrate efficacy in treating AD. However, benefits may depend on disease stage, dietary factors, and genetic status.", "population_specificity": "Individuals with or at risk of neurological and psychiatric disorders, including Alzheimer's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:47.969383+00:00"}
{"study_id": 201445, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) supplementation on mental health and behavior across different life stages.", "results_summary": "The study highlights that n-3 PUFA supplementation has been explored for various mental health conditions, including developmental disorders, depression, aggression, schizophrenia, cognitive decline, and dementia, but notes methodological differences and issues in the reviewed trials.", "population_specificity": "Individuals across the lifespan, from childhood developmental disorders to late adulthood cognitive decline and dementia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:48.071612+00:00"}
{"study_id": 201446, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of omega-3 fatty acids as neuromodulators and their potential efficacy as dietary supplements or prophylactic nutraceuticals for neurological and neuropsychiatric disorders.", "results_summary": "The study suggests omega-3 fatty acids regulate neurotransmission by modulating membrane properties and presynaptic vesicular release, potentially enhancing cognitive function and emotional coping. However, the evidence is tentative, relying on developmental and epidemiological data rather than direct clinical trials.", "population_specificity": "General nervous system function, with implications for neurological and neuropsychiatric disorders (no specific population mentioned).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:53.935643+00:00"}
{"study_id": 29234, "supplement_id": 1397, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to systematically review the scientific evidence on the association between oral intake of omega-6 fatty acids and metabolic syndrome components in adolescents.", "results_summary": "The study found no direct evaluation of omega-6 fatty acids' effect on metabolic syndrome, only on its components, with mixed and inconclusive results due to study heterogeneity.", "population_specificity": "Adolescents aged 10-19 years.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:54.540834+00:00"}
{"study_id": 29233, "supplement_id": 1397, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine if an animal protein-soybean oil-based broiler diet optimized net profit while affecting desirable \u03c9-6 fatty acids in the breast muscle of broiler chickens.", "results_summary": "The study found that animal protein and soybean oil increased broiler performance metrics (e.g., weight gain, feed efficiency) but reduced \u03c9-3 and \u03c9-6 fatty acids in breast muscle, while increasing saturated fatty acids.", "population_specificity": "Ross-308-day-old male broiler chicks", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:55.317434+00:00"}
{"study_id": 29235, "supplement_id": 1397, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine how omega-6 fatty acids (from evening primrose oil) regulate platelet function and reduce thrombotic risk in postmenopausal women.", "results_summary": "Omega-6 fatty acid supplementation attenuated thrombin receptor PAR4-induced platelet aggregation, decreased dense granule secretion, and reduced basal integrin \u03b1IIb\u03b23 activation, with effects persisting after washout.", "population_specificity": "Postmenopausal women", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:55.737952+00:00"}
{"study_id": 29232, "supplement_id": 1397, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the role of Aldh9a1b in detoxifying tt-DDE, a reactive metabolite of omega-6 fatty acids, and its impact on microvascular damage and glucose metabolism.", "results_summary": "The study found that Aldh9a1b deficiency or tt-DDE exposure led to insulin resistance, impaired glucose homeostasis, and abnormal retinal vasculature in zebrafish, which could be rescued by insulin sensitizers like metformin and rosiglitazone.", "population_specificity": "Zebrafish (larval and adult)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:55.900174+00:00"}
{"study_id": 29231, "supplement_id": 1397, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effect of the APOA5 gene variant (rs662799) on lipid profile changes in obese patients following a hypocaloric Mediterranean diet enriched with omega-6 polyunsaturated fatty acids (PUFA).", "results_summary": "The study found that non-C allele carriers showed significant improvements in insulin levels, HOMA-IR, and triglyceride levels after the intervention, while C allele carriers had a worse response in these parameters. Both genotype groups experienced improvements in adiposity, blood pressure, cholesterol levels, and adipokines.", "population_specificity": "362 Caucasian patients with obesity.", "effective_dosage": "Not specified.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:55.973177+00:00"}
